aminolevulinic acid has been researched along with Carcinoma, Basal Cell, Pigmented in 304 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Photodynamic therapy using topical methyl 5-aminolevulinate (MAL) is a new treatment modality for basal cell carcinoma (BCC) and actinic keratosis (AK)." | 9.12 | Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. ( Angell-Petersen, E; Giercksky, KE; Moan, J; Peng, Q; Soler, AM; Sørensen, R; Warloe, T, 2006) |
| "In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain." | 7.74 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Photodynamic therapy with topical delta-aminolevulinic acid using approximately 40 mW/cm(2) at 633 nm is photodynamically efficient with minimum pain." | 7.74 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Pain was assessed pre-illumination, during, and immediately after illumination, using a numeric rating scale." | 6.72 | Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. ( Haedersdal, M; Philipsen, PA; Skiveren, J; Wiegell, SR; Wulf, HC, 2006) |
| "Pain was monitored." | 5.35 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "When PpIX was 90% bleached, irradiance was increased to 150 mW/cm(2) until 200 J/cm(2) were delivered." | 5.35 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Once PpIX is largely photobleached, higher irradiances allow efficient, rapid delivery of additional light." | 5.35 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Photodynamic therapy using topical methyl 5-aminolevulinate (MAL) is a new treatment modality for basal cell carcinoma (BCC) and actinic keratosis (AK)." | 5.12 | Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. ( Angell-Petersen, E; Giercksky, KE; Moan, J; Peng, Q; Soler, AM; Sørensen, R; Warloe, T, 2006) |
| "Photodynamic therapy (PDT) using topical delta-aminolevulinic acid (delta-ALA) is an effective treatment for Bowen disease and certain basal cell carcinomas (BCCs), but its place in clinical practice remains to be established." | 5.09 | Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. ( MacKie, RM; McColl, JH; Moore, JV; Morton, CA; Whitehurst, C, 2001) |
| " Currently, aminolevulinic acid-mediated dPDT has been approved to treat actinic keratosis patients in Europe." | 5.05 | Daylight Photodynamic Therapy: An Update. ( Chen, H; Hsu, R; Lee, CN; Wong, TW, 2020) |
| "Methyl aminolevulinate (MAL), an ester of aminolevulinic acid, has been used effectively as a topical photosensitizing agent in the photodynamic therapy (PDT) of epidermal lesions such as actinic keratosis (AK) and basal cell carcinoma (BCC)." | 4.82 | Topical methyl aminolevulinate. ( Perry, CM; Scott, LJ; Siddiqui, MA, 2004) |
| "Photodynamic therapy (PDT) with topical δ-aminolevulinic acid (ALA) of non-melanoma skin cancers is often associated with treatment-limiting pain." | 3.79 | A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. ( Foster, TH; Henderson, BW; Housel, JP; Paquette, AD; Shi, Y; Wilding, GE; Zeitouni, NC, 2013) |
| "In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain." | 3.74 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Photodynamic therapy with topical delta-aminolevulinic acid using approximately 40 mW/cm(2) at 633 nm is photodynamically efficient with minimum pain." | 3.74 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Non-melanoma skin cancer is the most prevalent cancer type in Brazil and worldwide." | 2.79 | Experience and BCC subtypes as determinants of MAL-PDT response: preliminary results of a national Brazilian project. ( Bagnato, VS; Buzzá, HH; de Andrade, CT; Greco, C; Inada, NM; Kurachi, C; Moriyama, LT; Pires, L; Ramirez, DP; Salvio, AG; Vollet Filho, JD, 2014) |
| "A protocol was defined for the treatment of basal cell carcinoma with 20% MAL cream application." | 2.79 | Experience and BCC subtypes as determinants of MAL-PDT response: preliminary results of a national Brazilian project. ( Bagnato, VS; Buzzá, HH; de Andrade, CT; Greco, C; Inada, NM; Kurachi, C; Moriyama, LT; Pires, L; Ramirez, DP; Salvio, AG; Vollet Filho, JD, 2014) |
| " This method of enhancement was safely applied to a clinical PDT protocol with no unexpected adverse effects reported." | 2.73 | Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. ( Campbell, S; Curnow, A; Pye, A, 2008) |
| "This limits the treatment of basal cell carcinoma (non-melanoma skin cancer) to superficial forms and nodular therapy (only in aesthetically desired locations)." | 2.73 | Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. ( Smucler, R; Vlk, M, 2008) |
| "Pain was assessed pre-illumination, during, and immediately after illumination, using a numeric rating scale." | 2.72 | Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. ( Haedersdal, M; Philipsen, PA; Skiveren, J; Wiegell, SR; Wulf, HC, 2006) |
| "Conventional treatment of basal cell carcinoma (BCC) causes morbidity and/or disfigurement in some patients because of the location (e." | 2.71 | Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. ( De Rie, M; Fritsch, C; Horn, M; Kaufmann, R; Larkö, O; Legat, FJ; Rhodes, LE; Solér, AM; Stender, IM; Warloe, T; Wennberg, AM; Wolf, P; Wong, GA; Wulf, HC, 2003) |
| "After a single treatment, 47 (85%) basal cell carcinomas showed a complete response at a follow-up time of at least 6 months." | 2.69 | Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion. ( Hänggi, G; Hürlimann, AF; Panizzon, RG, 1998) |
| "There was a patient with Bowen's disease of the penis." | 2.69 | [Topical photodynamic therapy in basal and squamous cell carcinoma and penile Bowen's disease with 20% aminolevulinic acid, and exposure to red light and infrared light]. ( Harth, Y; Hirshovitz, B, 1998) |
| "For large areas of Bowen's disease, particularly in anatomically difficult areas and in elderly patients, PDT using ALA may constitute a single simple alternative outpatient treatment to existing therapies." | 2.67 | Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. ( Ash, DV; Brown, SB; Cairnduff, F; Hudson, EJ; Stringer, MR, 1994) |
| "Surgical excision (SE) is a first-line treatment for basal cell carcinoma (BCC)." | 2.53 | Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis. ( Han, J; Li, J; Lin, H; Luo, X; Ye, Z; Yu, J; Zhao, Y; Zou, Y, 2016) |
| "With regard to squamous cell carcinoma, treatment with 5-fluorouracil, methotrexate, interferon, and bleomycin are reviewed." | 2.47 | Intralesional agents in the management of cutaneous malignancy: a review. ( Good, LM; High, WA; Miller, MD, 2011) |
| "We report treatment of two nevoid basal cell carcinoma syndrome patients, women aged 21 and 47, with 20%delta-aminolevulinic acid solution and 417-nm blue light source (irradiance 10 mW/cm(2))." | 2.42 | delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. ( Gilchrest, BA; Itkin, A, 2004) |
| "Patients with nevoid basal cell carcinoma syndrome suffer from multiple basal cell carcinomas, requiring numerous surgical procedures that over time leave them with multiple disfiguring scars." | 2.42 | delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. ( Gilchrest, BA; Itkin, A, 2004) |
| "No new basal cell carcinomas were observed during the 8-month follow-up period in areas treated with a broad application technique." | 2.42 | delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. ( Gilchrest, BA; Itkin, A, 2004) |
| "The incidence of basal cell carcinoma is increasing." | 2.41 | Basal cell carcinoma--new aspects of diagnosis and treatment. ( Wennberg, AM, 2000) |
| "Non-melanoma skin cancer (NMSC) is the most common malignancy worldwide, with rising incidence in the recent years." | 1.72 | In vitro 5-Fluorouracil resistance produces enhanced photodynamic therapy damage in SCC and tumor resistance in BCC. ( Gilaberte, Y; González, S; Gutiérrez-Pérez, M; Juarranz, Á; Nicolás-Morala, J; Portillo-Esnaola, M; Terrén, S, 2022) |
| "As for side effects, hypertrophic scar and pain were observed." | 1.62 | Bimodal photodynamic therapy for treatment of a 91-year-old patient with locally advanced cutaneous basal cell carcinoma and postoperative scar management. ( Liao, C; Shi, L; Wang, D; Wang, X, 2021) |
| "Basal cell carcinoma is the most common cancer." | 1.62 | Treatment of cutaneous basal cell carcinoma with combined laser extirpation and methyl aminolevulinic acid: five-year success rates. ( Abdelrahman, W; Azzopardi, E; Azzopardi, EA; Barbara, C; Camilleri, L; Clementoni, MT; Miles, N; Murison, M; O'Leary, B; Yarrow, J, 2021) |
| "Nodular basal cell carcinoma was the most common subtype (41." | 1.62 | Treatment of cutaneous basal cell carcinoma with combined laser extirpation and methyl aminolevulinic acid: five-year success rates. ( Abdelrahman, W; Azzopardi, E; Azzopardi, EA; Barbara, C; Camilleri, L; Clementoni, MT; Miles, N; Murison, M; O'Leary, B; Yarrow, J, 2021) |
| "The purpose of this study is to investigate the clinical efficacy of Mohs surgery in combination with topical photodynamic therapy (PDT) for facial basal cell carcinoma." | 1.56 | Clinical efficacy of Mohs surgery combined with topical photodynamic therapy for facial basal cell carcinoma. ( Kou, H; Lu, Y; Wang, Y; Yang, Y; Zhang, J; Zhang, X, 2020) |
| "PDT in combination with limited surgery is a safe, effective and minimally-invasive approach for treating orbital BCC." | 1.51 | Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma. ( Kou, H; Li, G; Li, X; Lu, Y; Tan, L; Wang, Y; Zhang, J, 2019) |
| "In our study, 8 patients with periocular basal cell carcinoma were treated with topical aminolevulinic acid photodynamic therapy (ALA-PDT) combined with surgery." | 1.51 | Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma. ( Kou, H; Li, G; Li, X; Lu, Y; Tan, L; Wang, Y; Zhang, J, 2019) |
| " The purpose of this article was to study the anti-tumor effect of ALA-PDT combined with limited excision in periocular basal cell carcinoma (BCC) and its role in improving the effect of the operation." | 1.51 | Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma. ( Kou, H; Li, G; Li, X; Lu, Y; Tan, L; Wang, Y; Zhang, J, 2019) |
| "Superficial basal cell carcinoma is a type of keratinocyte carcinoma that has increasing incidence and substantial morbidity." | 1.48 | Comparing Topical Treatments for Basal Cell Carcinoma. ( Shaw, FM; Weinstock, MA, 2018) |
| "Treating skin cancers and extensive actinic keratosis in patients with bullous pemphigoid (BP) can be challenging." | 1.46 | Photodynamic therapy effective for the treatment of actinic keratosis and basal cell carcinoma in bullous pemphigoid patients. ( Canavan, TN; de la Feld, SF; Huang, C; Sami, N, 2017) |
| "We report the successful use of PDT to treat actinic keratosis and skin cancers in two patients with BP, both of whom had excellent response to PDT and tolerated treatment without any bullous disease flares." | 1.46 | Photodynamic therapy effective for the treatment of actinic keratosis and basal cell carcinoma in bullous pemphigoid patients. ( Canavan, TN; de la Feld, SF; Huang, C; Sami, N, 2017) |
| "The PDT combined with a topical photosensitizer 5-aminolevulinic acid (ALA) and an intravenously injected light-sensitive agent hematoporphyrin derivative (HPD) was used to treat 26 patients with 41 skin cancer lesions in head and face." | 1.43 | A photodynamic therapy combined with topical 5-aminolevulinic acid and systemic hematoporphyrin derivative is more efficient but less phototoxic for cancer. ( Lin, Y; Wang, Y; Zhang, HG; Zhu, J, 2016) |
| "Patients with Gorlin syndrome develop multiple basal cell carcinomas (BCC), for which treatment is often difficult." | 1.40 | Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy. ( Basset-Seguin, N; Bissonnette, R; Girard, C; Haedersdal, M; Lear, JT; Paul, C; Piaserico, S, 2014) |
| "Pain was assessed using a visual analog scale (VAS)." | 1.39 | A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. ( Foster, TH; Henderson, BW; Housel, JP; Paquette, AD; Shi, Y; Wilding, GE; Zeitouni, NC, 2013) |
| "Pain was strongly influenced by lesion location but not by lesion type, number, or size." | 1.39 | A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. ( Foster, TH; Henderson, BW; Housel, JP; Paquette, AD; Shi, Y; Wilding, GE; Zeitouni, NC, 2013) |
| "Two of three Bowen's disease lesions showed a complete response." | 1.39 | A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. ( Foster, TH; Henderson, BW; Housel, JP; Paquette, AD; Shi, Y; Wilding, GE; Zeitouni, NC, 2013) |
| "The incidence of nonmelanoma skin cancer is significantly increased in recipients of solid-organ transplants." | 1.38 | Photodynamic therapy for basal cell carcinomas in organ-transplant recipients. ( Guleng, GE; Helsing, P, 2012) |
| "They included squamous cell carcinoma (SCC), basal cell carcinoma (BCC), Bowen's disease (BD), mammary and extramammary Paget disease, actinic keratosis (AK) and erythroplasia of Queyrat." | 1.35 | Treatment of skin cancer and pre-cancer using topical ALA-PDT--a single hospital experience. ( Guo, MX; Wang, HW; Wang, XL; Xu, SZ, 2008) |
| "So far, we have treated 76 cases of skin cancer and pre-cancer using topical ALA-PDT." | 1.35 | Treatment of skin cancer and pre-cancer using topical ALA-PDT--a single hospital experience. ( Guo, MX; Wang, HW; Wang, XL; Xu, SZ, 2008) |
| "Twelve patients with Bowen's disease (eight) and superficial basal cell carcinoma (four) < 2 cm in diameter were recruited into the study following histological confirmation of the diagnosis." | 1.35 | An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer. ( Attili, SK; Camacho-Lopez, M; Ferguson, J; Ibbotson, S; Lesar, A; McNeill, A; Moseley, H; Samuel, ID, 2009) |
| " However, in the case of deep, nodular-ulcerative lesions, the complete response rates are lower, possibly related to a lower bioavailability of PpIX." | 1.35 | Comparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma. ( Ballini, JP; Dögnitz, N; Gabrecht, T; Lange, N; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2008) |
| "Once PpIX is largely photobleached, higher irradiances allow efficient, rapid delivery of additional light." | 1.35 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "When PpIX was 90% bleached, irradiance was increased to 150 mW/cm(2) until 200 J/cm(2) were delivered." | 1.35 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Pain was monitored." | 1.35 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "Calcitriol pretreatment of the cells elevated their PpIX levels." | 1.35 | Calcitriol treatment improves methyl aminolaevulinate-based photodynamic therapy in human squamous cell carcinoma A431 cells. ( Cicarma, E; Juzeniene, A; Ma, LW; Moan, J; Tuorkey, M, 2009) |
| "Pain was assessed during illumination using a continuous visual analogue scale (VAS)." | 1.35 | Topical photodynamic therapy with porphyrin precursors--assessment of treatment-associated pain in a retrospective study. ( Babilas, P; Karrer, S; Landthaler, M; Schreml, S; Steinbauer, JM; Szeimies, RM; Zeman, F, 2009) |
| "Exclusion of unilateral nevoid basal cell carcinoma syndrome is indicated." | 1.33 | Unilateral Basal cell carcinomas: an unusual entity treated with photodynamic therapy. ( Allen, JH; Lane, JE; Lane, TN; Lesher, JL, 2005) |
| "Like nevoid basal cell carcinoma syndrome, unilateral basal cell carcinomas poses a therapeutic challenge with the sheer number of cutaneous tumors." | 1.33 | Unilateral Basal cell carcinomas: an unusual entity treated with photodynamic therapy. ( Allen, JH; Lane, JE; Lane, TN; Lesher, JL, 2005) |
| "Aminolevulinic acid (ALA) is a charged, hydrophilic molecule that penetrates poorly through cellular structures." | 1.32 | Evaluation of the penetration of 5-aminolevulinic acid through basal cell carcinoma: a pilot study. ( Ahmadi, S; Donnelly, RF; McCarron, PA; McKenna, K; Woolfson, AD, 2004) |
| "It is a new alternative modality for skin cancer therapies." | 1.31 | Evaluation of photodynamic therapy of skin cancers with partial differential alpha-aminolevulinic acid. ( Wang, X; Xia, Y; Xu, S; Xu, W; Zhang, C, 2002) |
| "The two principal locations of the 10 Bowen's disease lesions were the leg (50%) and the trunk (40%)." | 1.29 | Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. ( Andersson, T; Andersson-Engels, S; Berg, R; Johansson, J; Killander, D; Stenram, U; Svanberg, K; Svanberg, S; Wang, I, 1994) |
| "Ten basal cell carcinomas were coated with an ointment containing 10% ALA prior to excision; five served as controls." | 1.29 | Penetration potency of topical applied delta-aminolevulinic acid for photodynamic therapy of basal cell carcinoma. ( Landthaler, M; Sassy, T; Szeimies, RM, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 41 (13.49) | 18.2507 |
| 2000's | 111 (36.51) | 29.6817 |
| 2010's | 119 (39.14) | 24.3611 |
| 2020's | 33 (10.86) | 2.80 |
| Authors | Studies |
|---|---|
| Ibbotson, SH | 6 |
| Ferguson, J | 6 |
| Moseley, H | 9 |
| Samuel, IDW | 1 |
| Lesar, A | 3 |
| Dawe, RS | 2 |
| Liao, C | 2 |
| Shi, L | 2 |
| Wang, D | 2 |
| Wang, X | 4 |
| Salvio, AG | 4 |
| Veneziano, DB | 1 |
| Moriyama, LT | 2 |
| Inada, NM | 2 |
| Grecco, C | 1 |
| Kurachi, C | 2 |
| Bagnato, VS | 4 |
| Condorelli, AG | 1 |
| Motolese, A | 2 |
| Borgia, F | 1 |
| Bartolomeo, LD | 1 |
| Bianchi, L | 1 |
| Rossi, PG | 1 |
| Ottone, M | 1 |
| Guarneri, F | 1 |
| van Delft, LCJ | 2 |
| Nelemans, PJ | 8 |
| Kessels, JPHM | 2 |
| Kreukels, H | 2 |
| Roozeboom, MH | 8 |
| de Rooij, MJM | 1 |
| Mosterd, K | 12 |
| de Haas, ERM | 2 |
| Kelleners-Smeets, NWJ | 4 |
| Nicolás-Morala, J | 1 |
| Portillo-Esnaola, M | 1 |
| Terrén, S | 1 |
| Gutiérrez-Pérez, M | 1 |
| Gilaberte, Y | 4 |
| González, S | 5 |
| Juarranz, Á | 4 |
| Yang, W | 2 |
| Liu, L | 1 |
| Thompson, A | 1 |
| Mattia, A | 1 |
| Green, WH | 2 |
| Cognetta, AB | 2 |
| Evangelou, G | 3 |
| Koumaki, D | 1 |
| Fragiadaki, I | 1 |
| Chaniotis, V | 1 |
| Farrar, MD | 2 |
| Karatzi, C | 1 |
| Sotiriou, E | 6 |
| Giannikaki, E | 1 |
| Katoulis, A | 1 |
| Papadakis, M | 1 |
| Lallas, A | 4 |
| Stefanidou, M | 1 |
| Krueger-Krasagakis, S | 1 |
| Rhodes, LE | 7 |
| Krasagakis, K | 1 |
| Lultschik, S | 1 |
| Tran, J | 1 |
| Sapra, S | 1 |
| Sharma, K | 1 |
| Dong, K | 1 |
| Xu, S | 2 |
| Zhang, L | 2 |
| Zhang, M | 2 |
| Fu, C | 2 |
| Qin, L | 2 |
| Zeng, XY | 2 |
| Wang, BC | 2 |
| Cao, D | 1 |
| Zhu, W | 1 |
| Kuang, Y | 1 |
| Zhao, S | 1 |
| Hellen, R | 1 |
| Nic Dhonncha, E | 1 |
| Havelin, A | 1 |
| Fleming, L | 1 |
| Kavanagh, A | 1 |
| Lally, A | 1 |
| Kirby, B | 1 |
| Moriarty, B | 1 |
| Collins, P | 1 |
| Ferrara, F | 1 |
| Lacava, R | 1 |
| Barisani, A | 1 |
| Messori, S | 1 |
| Patrizi, A | 1 |
| Bardazzi, F | 1 |
| Vaccari, S | 1 |
| Gubarkova, EV | 1 |
| Feldchtein, FI | 1 |
| Zagaynova, EV | 1 |
| Gamayunov, SV | 1 |
| Sirotkina, MA | 1 |
| Sedova, ES | 1 |
| Kuznetsov, SS | 1 |
| Moiseev, AA | 1 |
| Matveev, LA | 1 |
| Zaitsev, VY | 1 |
| Karashtin, DA | 1 |
| Gelikonov, GV | 1 |
| Pires, L | 2 |
| Vitkin, A | 1 |
| Gladkova, ND | 1 |
| Liu, Q | 1 |
| Logan, IT | 1 |
| Kulakov, EL | 1 |
| Perrett, CM | 2 |
| Filonenko, E | 1 |
| Kaprin, A | 1 |
| Urlova, A | 1 |
| Grigorievykh, N | 1 |
| Ivanova-Radkevich, V | 1 |
| Stringasci, MD | 2 |
| Barreto Requena, M | 1 |
| Darr-Foit, S | 1 |
| Elsner, P | 1 |
| Goetze, S | 1 |
| Salmivuori, M | 1 |
| Grönroos, M | 1 |
| Tani, T | 1 |
| Pölönen, I | 1 |
| Räsänen, J | 1 |
| Annala, L | 1 |
| Snellman, E | 1 |
| Neittaanmäki, N | 1 |
| Stephens, R | 1 |
| Holmes, J | 1 |
| Eadie, E | 1 |
| Kapek, Ł | 1 |
| Cholewka, A | 3 |
| Szurko, A | 1 |
| Sieroń, K | 1 |
| Sieroń, A | 1 |
| Kwiatek, S | 2 |
| Stanek, A | 2 |
| Woźniak, Z | 1 |
| Trzeciakowski, W | 1 |
| Chlebicka, I | 1 |
| Ziółkowski, P | 2 |
| Queirós, C | 1 |
| Garrido, PM | 1 |
| Maia Silva, J | 1 |
| Filipe, P | 1 |
| Li, C | 2 |
| Chen, P | 1 |
| Li, Z | 1 |
| Wang, Y | 4 |
| He, S | 1 |
| Shi, M | 1 |
| Wang, Q | 1 |
| Xu, M | 1 |
| Li, Q | 2 |
| Chen, H | 2 |
| Zeng, K | 1 |
| Liang, J | 1 |
| Zhang, X | 2 |
| Zhang, J | 2 |
| Lu, Y | 2 |
| Yang, Y | 1 |
| Kou, H | 2 |
| De Luca, EV | 1 |
| Tambone, S | 1 |
| Catapano, S | 1 |
| Fossati, B | 1 |
| Peris, K | 3 |
| Lee, CN | 1 |
| Hsu, R | 1 |
| Wong, TW | 1 |
| Thomson, J | 1 |
| Hogan, S | 1 |
| Leonardi-Bee, J | 1 |
| Williams, HC | 1 |
| Bath-Hextall, FJ | 1 |
| Navarro-Triviño, FJ | 1 |
| Ayén-Rodríguez, Á | 1 |
| Llamas-Molina, JM | 1 |
| Saenz-Guirado, S | 1 |
| Ruiz-Villaverde, R | 1 |
| Requena, MB | 1 |
| Pierre, MBR | 1 |
| Gómez, C | 1 |
| Cobos, P | 1 |
| Alberdi, E | 1 |
| Gracia-Cazaña, T | 3 |
| Nicolás, J | 1 |
| Cerro-Muñoz, PA | 1 |
| Azzopardi, EA | 1 |
| Abdelrahman, W | 1 |
| Azzopardi, E | 1 |
| O'Leary, B | 2 |
| Yarrow, J | 1 |
| Miles, N | 1 |
| Barbara, C | 1 |
| Camilleri, L | 1 |
| Clementoni, MT | 1 |
| Murison, M | 2 |
| Zhang, G | 2 |
| Wang, P | 2 |
| Sun, X | 1 |
| Canavan, TN | 1 |
| de la Feld, SF | 1 |
| Huang, C | 1 |
| Sami, N | 1 |
| Sung, JM | 1 |
| Kim, YC | 1 |
| Essers, BAB | 2 |
| Arits, AH | 6 |
| Hendriks, MR | 1 |
| Kelleners-Smeets, NW | 9 |
| van Pelt, H | 1 |
| Jansen, MHE | 2 |
| Arits, AHMM | 2 |
| Sommer, A | 2 |
| van Pelt, HPA | 1 |
| Quaedvlieg, PJF | 1 |
| Steijlen, PM | 4 |
| Rizzo, JM | 1 |
| Segal, RJ | 1 |
| Zeitouni, NC | 4 |
| JalalKamali, M | 1 |
| Nematollahi-Mahani, SN | 1 |
| Shojaei, M | 1 |
| Shamsoddini, A | 1 |
| Arabpour, N | 1 |
| Zhang, S | 1 |
| Yang, L | 1 |
| Yu, R | 1 |
| Hu, N | 1 |
| Suárez Valladares, MJ | 2 |
| Vega, J | 1 |
| Rodríguez Prieto, MA | 3 |
| Shaw, FM | 1 |
| Weinstock, MA | 1 |
| Morton, CA | 8 |
| Dominicus, R | 1 |
| Radny, P | 1 |
| Dirschka, T | 1 |
| Hauschild, A | 1 |
| Reinhold, U | 1 |
| Aschoff, R | 1 |
| Ulrich, M | 1 |
| Keohane, S | 1 |
| Ekanayake-Bohlig, S | 1 |
| Ibbotson, S | 8 |
| Ostendorf, R | 1 |
| Berking, C | 2 |
| Gröne, D | 1 |
| Schulze, HJ | 1 |
| Ockenfels, HM | 1 |
| Jasnoch, V | 1 |
| Kurzen, H | 1 |
| Sebastian, M | 1 |
| Stege, H | 1 |
| Staubach, P | 1 |
| Gupta, G | 1 |
| Hübinger, F | 1 |
| Ziabreva, I | 1 |
| Schmitz, B | 1 |
| Gertzmann, A | 1 |
| Lübbert, H | 1 |
| Szeimies, RM | 10 |
| Maytin, EV | 1 |
| Kaw, U | 1 |
| Ilyas, M | 1 |
| Mack, JA | 1 |
| Hu, B | 1 |
| Suárez-Valladares, MJ | 1 |
| Calleja-Antolín, SM | 1 |
| García Ruíz de Morales, JM | 1 |
| Vega-Gutierrez, J | 1 |
| Vrani, F | 1 |
| Lazaridou, E | 2 |
| Vakirlis, E | 1 |
| Sideris, N | 1 |
| Kirmanidou, E | 1 |
| Apalla, Z | 5 |
| Ioannides, D | 5 |
| Neal, DE | 1 |
| Smith, RJ | 1 |
| Aberbigbe, O | 1 |
| Etzkorn, JR | 1 |
| Lydon, E | 1 |
| Lim, HW | 1 |
| Olasz, A | 1 |
| Christensen, E | 4 |
| Braun, R | 1 |
| Foss, OA | 1 |
| Dotterud, LK | 1 |
| Hamid, MA | 1 |
| Nguyen, K | 1 |
| Khachemoune, A | 1 |
| Alique-García, S | 1 |
| Company-Quiroga, J | 1 |
| Sánchez Campos, A | 1 |
| Hernández Núñez, A | 1 |
| Borbujo, J | 1 |
| Mascaraque, M | 1 |
| Lucena, SR | 1 |
| Vera-Álvarez, J | 1 |
| Li, X | 1 |
| Tan, L | 1 |
| Li, G | 1 |
| Shokrollahi, K | 1 |
| Javed, M | 1 |
| Aeuyung, K | 1 |
| Ghattaura, A | 1 |
| Whitaker, IS | 1 |
| James, W | 1 |
| Borroni, RG | 1 |
| Carugno, A | 1 |
| Rivetti, N | 1 |
| Arbustini, E | 1 |
| Brazzelli, V | 1 |
| Aardoom, MA | 1 |
| Thissen, MR | 3 |
| Kuijpers, DI | 3 |
| Basset-Seguin, N | 3 |
| Bissonnette, R | 3 |
| Girard, C | 1 |
| Haedersdal, M | 4 |
| Lear, JT | 4 |
| Paul, C | 1 |
| Piaserico, S | 1 |
| Matei, C | 1 |
| Tampa, M | 1 |
| Poteca, T | 1 |
| Panea-Paunica, G | 1 |
| Georgescu, SR | 1 |
| Ion, RM | 1 |
| Popescu, SM | 1 |
| Giurcaneanu, C | 1 |
| Dummer, R | 3 |
| Essers, BA | 2 |
| Spoorenberg, E | 2 |
| De Rooij, MJ | 1 |
| van Pelt, HP | 1 |
| Quaedvlieg, PJ | 1 |
| Krekels, GA | 1 |
| van Neer, PA | 1 |
| Rijzewijk, JJ | 1 |
| van Geest, AJ | 1 |
| Lippert, J | 2 |
| Smucler, R | 3 |
| Vlk, M | 3 |
| Griškjans, Ž | 1 |
| Derjabo, A | 2 |
| Čēma, I | 1 |
| Arits, A | 2 |
| Collier, NJ | 1 |
| Ali, FR | 1 |
| Themstrup, L | 1 |
| Banzhaf, CA | 1 |
| Mogensen, M | 1 |
| Jemec, GB | 1 |
| Tzellos, T | 1 |
| Sidiropoulos, T | 1 |
| Lefaki, I | 2 |
| Trakatelli, M | 1 |
| Patsatsi, A | 1 |
| Kyrgidis, A | 1 |
| Stratigos, A | 1 |
| Zalaudek, I | 1 |
| Argenziano, G | 1 |
| Ramirez, DP | 1 |
| Vollet Filho, JD | 1 |
| Buzzá, HH | 1 |
| de Andrade, CT | 1 |
| Greco, C | 1 |
| Nelemans, P | 4 |
| Dixon, AJ | 1 |
| Anderson, SJ | 1 |
| Mazzurco, JD | 1 |
| Steinman, HK | 1 |
| Haak, CS | 1 |
| Togsverd-Bo, K | 2 |
| Thaysen-Petersen, D | 1 |
| Wulf, HC | 6 |
| Paasch, U | 1 |
| Anderson, RR | 5 |
| Samy, NA | 1 |
| Salah, MM | 1 |
| Ali, MF | 1 |
| Sadek, AM | 1 |
| Fai, D | 2 |
| Romano, I | 2 |
| Fai, C | 1 |
| Cassano, N | 2 |
| Vena, GA | 2 |
| Sunar, U | 1 |
| Rohrbach, DJ | 1 |
| Paquette, AD | 3 |
| Bellnier, DA | 1 |
| Shi, Y | 2 |
| Wilding, G | 1 |
| Foster, TH | 4 |
| Henderson, BW | 2 |
| Lecluse, LL | 1 |
| Spuls, PI | 1 |
| Kelleners-Smeets, N | 2 |
| Nijsten, T | 1 |
| de Haas, ER | 6 |
| van Kleef, L | 1 |
| Winnepenninckx, VJ | 1 |
| van Marion, AM | 1 |
| van der Beek, N | 2 |
| Bjerring, P | 2 |
| Neumann, HA | 7 |
| Savoia, P | 1 |
| Deboli, T | 1 |
| Previgliano, A | 1 |
| Broganelli, P | 1 |
| Kulyk, O | 1 |
| Valentine, RM | 2 |
| Samuel, ID | 2 |
| Choi, SH | 1 |
| Kim, KH | 2 |
| Song, KH | 1 |
| Lin, Y | 1 |
| Zhang, HG | 1 |
| Zhu, J | 1 |
| Cieślar, G | 1 |
| Straszak, D | 1 |
| Gibińska, J | 1 |
| Sieroń-Stołtny, K | 1 |
| Kessels, J | 1 |
| Hendriks, J | 1 |
| El Hoshy, K | 1 |
| Bosseila, M | 1 |
| El Sharkawy, D | 1 |
| Sobhi, R | 1 |
| Tarstedt, M | 1 |
| Gillstedt, M | 2 |
| Wennberg Larkö, AM | 1 |
| Paoli, J | 2 |
| Hoogedoorn, L | 1 |
| Hendriks, JC | 1 |
| Knuiman, GJ | 1 |
| Blokx, WA | 1 |
| van de Kerkhof, PC | 1 |
| van Erp, PE | 1 |
| Gerritsen, MJ | 1 |
| Zou, Y | 1 |
| Zhao, Y | 1 |
| Yu, J | 1 |
| Luo, X | 1 |
| Han, J | 1 |
| Ye, Z | 1 |
| Li, J | 1 |
| Lin, H | 1 |
| Mühlstädt, M | 1 |
| Pérez Paredes, MG | 1 |
| González Sixto, B | 1 |
| Bu, W | 1 |
| Zhang, Q | 1 |
| Yuan, C | 1 |
| Chen, X | 1 |
| Fang, F | 1 |
| Hambly, R | 1 |
| Mansoor, N | 2 |
| Quinlan, C | 2 |
| Shah, Z | 2 |
| Lenane, P | 2 |
| Ralph, N | 2 |
| Moloney, FJ | 2 |
| Shokeen, D | 1 |
| Niculescu, L | 1 |
| Bierhoff, E | 1 |
| Hartmann, D | 1 |
| Ruzicka, T | 7 |
| Braunmühl, TV | 1 |
| Hambly, RA | 1 |
| Toll, A | 1 |
| Parera, ME | 1 |
| Vélez, M | 1 |
| Pujol, RM | 1 |
| Campbell, SM | 3 |
| Alyahya, R | 1 |
| Horton, S | 2 |
| Pye, A | 3 |
| Curnow, A | 6 |
| Madan, V | 1 |
| West, CA | 1 |
| Murphy, JV | 1 |
| Murrell, DF | 3 |
| Rubel, D | 1 |
| Frambach, Y | 1 |
| de Berker, D | 1 |
| Kerrouche, N | 1 |
| Villemagne, H | 1 |
| Cottrell, WJ | 2 |
| Keymel, KR | 1 |
| Oseroff, AR | 5 |
| Devirgiliis, V | 1 |
| Panasiti, V | 1 |
| Curzio, M | 1 |
| Gobbi, S | 1 |
| Rossi, M | 1 |
| Roberti, V | 1 |
| Calvieri, S | 1 |
| Sandberg, C | 3 |
| Halldin, CB | 2 |
| Ericson, MB | 4 |
| Larkö, O | 9 |
| Krogstad, AL | 2 |
| Wennberg, AM | 10 |
| Janssen, RL | 1 |
| Broekhof, KG | 1 |
| Skogvoll, E | 2 |
| Viset, T | 1 |
| Warloe, T | 9 |
| Sundstrøm, S | 1 |
| Dögnitz, N | 1 |
| Salomon, D | 1 |
| Zellweger, M | 1 |
| Ballini, JP | 1 |
| Gabrecht, T | 1 |
| Lange, N | 1 |
| van den Bergh, H | 1 |
| Wagnières, G | 1 |
| Neus, S | 1 |
| Gambichler, T | 2 |
| Bechara, FG | 1 |
| Wöhl, S | 1 |
| Lehmann, P | 5 |
| de Bruijn, HS | 1 |
| Sterenborg, HJ | 5 |
| Robinson, DJ | 5 |
| Calista, D | 1 |
| Prignano, F | 2 |
| Lotti, T | 1 |
| Spallanzani, A | 1 |
| Berti, S | 1 |
| de Giorgi, V | 1 |
| Moretti, S | 1 |
| Attili, SK | 1 |
| McNeill, A | 1 |
| Camacho-Lopez, M | 1 |
| Wang, XL | 1 |
| Wang, HW | 1 |
| Guo, MX | 1 |
| Xu, SZ | 1 |
| Downs, AM | 1 |
| Bower, CB | 1 |
| Oliver, DA | 1 |
| Stone, CA | 1 |
| Cicarma, E | 1 |
| Tuorkey, M | 1 |
| Juzeniene, A | 2 |
| Ma, LW | 1 |
| Moan, J | 6 |
| Kotimäki, J | 1 |
| Arpaia, N | 1 |
| Vestita, M | 1 |
| Steinbauer, JM | 1 |
| Schreml, S | 1 |
| Babilas, P | 1 |
| Zeman, F | 1 |
| Karrer, S | 4 |
| Landthaler, M | 6 |
| Wang, KK | 1 |
| Mitra, S | 1 |
| Chovarda, E | 1 |
| Devliotou-Panagiotidou, D | 1 |
| Caekelbergh, K | 2 |
| Nikkels, AF | 1 |
| Leroy, B | 1 |
| Verhaeghe, E | 1 |
| Lamotte, M | 1 |
| Vincent, R | 1 |
| Foley, P | 4 |
| Freeman, M | 1 |
| Menter, A | 1 |
| Siller, G | 1 |
| El-Azhary, RA | 1 |
| Gebauer, K | 2 |
| Lowe, NJ | 3 |
| Jarratt, MT | 1 |
| Rich, P | 1 |
| Pariser, DM | 2 |
| Barnetson, R | 1 |
| Anderson, C | 1 |
| Kossard, S | 1 |
| Gibson, LE | 1 |
| Tope, WD | 3 |
| Liutkeviciūte-Navickiene, J | 1 |
| Mordas, A | 1 |
| Simkute, S | 1 |
| Bloznelyte-Plesniene, L | 1 |
| Good, LM | 1 |
| Miller, MD | 1 |
| High, WA | 1 |
| Aguilar, M | 1 |
| de Troya, M | 1 |
| Martin, L | 1 |
| Benítez, N | 1 |
| González, M | 1 |
| Sebaratnam, DF | 1 |
| Venugopal, SS | 1 |
| Karen, JK | 1 |
| Hale, EK | 1 |
| Morrow, DI | 1 |
| McCarron, PA | 2 |
| Woolfson, AD | 2 |
| Juzenas, P | 1 |
| Iani, V | 1 |
| Donnelly, RF | 2 |
| Tyrrell, JS | 1 |
| Lee, CY | 1 |
| Kim, YH | 1 |
| Fasanmade, A | 1 |
| Milne, J | 1 |
| Taylor, D | 1 |
| Godden, D | 1 |
| Fantini, F | 2 |
| Greco, A | 2 |
| Del Giovane, C | 1 |
| Cesinaro, AM | 2 |
| Venturini, M | 2 |
| Zane, C | 1 |
| Surrenti, T | 2 |
| Calzavara-Pinton, PG | 3 |
| García Martín, E | 1 |
| Fernández Tirado, FJ | 1 |
| Gao, T | 1 |
| Jiao, B | 1 |
| Hu, X | 1 |
| Luan, Q | 1 |
| Li, K | 1 |
| Ma, C | 1 |
| Wang, S | 1 |
| Tierney, E | 1 |
| Petersen, J | 1 |
| Hanke, CW | 2 |
| Brown, CT | 1 |
| Wood, K | 1 |
| Torres, T | 1 |
| Fernandes, I | 1 |
| Costa, V | 1 |
| Selores, M | 1 |
| Prado, R | 1 |
| Francis, SO | 1 |
| Mason, MN | 1 |
| Wing, G | 1 |
| Gamble, RG | 1 |
| Dellavalle, R | 1 |
| Lindberg-Larsen, R | 1 |
| Sølvsten, H | 1 |
| Kragballe, K | 1 |
| Gaál, M | 2 |
| Otrosinka, S | 1 |
| Baltás, E | 1 |
| Ocsai, H | 1 |
| Oláh, J | 1 |
| Kemény, L | 2 |
| Gyulai, R | 2 |
| Lee, Y | 1 |
| Baron, ED | 2 |
| de Leeuw, J | 1 |
| Demmendal, C | 1 |
| Cotterell, L | 1 |
| Andrew, S | 1 |
| Tosca, AD | 2 |
| Watson, RE | 1 |
| Osiecka, B | 1 |
| Jurczyszyn, K | 1 |
| Mørk, C | 1 |
| Kriz, M | 1 |
| Guleng, GE | 1 |
| Helsing, P | 1 |
| Requena, C | 1 |
| Messeguer, F | 1 |
| Llombart, B | 1 |
| Serra-Guillén, C | 1 |
| Guillén, C | 1 |
| Marmur, ES | 2 |
| Nolan, KA | 1 |
| Henry, M | 1 |
| Cosgarea, R | 1 |
| Susan, M | 1 |
| Crisan, M | 1 |
| Senila, S | 1 |
| Kui, R | 1 |
| Hunyadi, Z | 1 |
| Blake, E | 2 |
| Allen, J | 2 |
| Thorn, C | 1 |
| Shore, A | 1 |
| de Vijlder, HC | 2 |
| Valentine, R | 1 |
| Hearn, R | 1 |
| Sala, R | 1 |
| Campbell, S | 2 |
| Mathew, J | 1 |
| Helliwell, P | 2 |
| Wolfe, CM | 1 |
| Hatfield, HK | 1 |
| Segura, S | 1 |
| Wiegell, SR | 2 |
| Skødt, V | 1 |
| Housel, JP | 1 |
| Wilding, GE | 1 |
| Xu, W | 1 |
| Xia, Y | 1 |
| Zhang, C | 1 |
| Gudmundson, F | 2 |
| Rosén, A | 3 |
| Pålsson, S | 2 |
| Gustafsson, L | 1 |
| Bendsoe, N | 3 |
| Soto Thompson, M | 1 |
| Andersson-Engels, S | 9 |
| Svanberg, K | 9 |
| Shieh, S | 1 |
| Choudry, K | 1 |
| Brooke, RC | 1 |
| Farrar, W | 1 |
| Clark, C | 1 |
| Bryden, A | 1 |
| Dawe, R | 1 |
| Brown, SB | 4 |
| Horn, M | 1 |
| Wolf, P | 6 |
| Fritsch, C | 7 |
| Kaufmann, R | 1 |
| De Rie, M | 2 |
| Legat, FJ | 1 |
| Stender, IM | 1 |
| Solér, AM | 7 |
| Wong, GA | 3 |
| Enström, Y | 1 |
| Groves, R | 1 |
| Morken, T | 1 |
| Goulden, V | 2 |
| Grob, JJ | 1 |
| Varma, S | 1 |
| Schmults, CD | 1 |
| Goldberg, DJ | 2 |
| Stiefelhagen, P | 1 |
| Siddiqui, MA | 1 |
| Perry, CM | 1 |
| Scott, LJ | 1 |
| Itkin, A | 1 |
| Gilchrest, BA | 2 |
| Kormeili, T | 1 |
| Yamauchi, PS | 1 |
| Ahmadi, S | 1 |
| McKenna, K | 2 |
| Dragieva, G | 1 |
| Prinz, BM | 1 |
| Hafner, J | 1 |
| Burg, G | 1 |
| Binswanger, U | 1 |
| Kempf, W | 1 |
| Podda, M | 1 |
| Naidenov, N | 1 |
| Dencheva, R | 1 |
| Tsankov, N | 1 |
| Cappugi, P | 2 |
| Mavilia, L | 2 |
| Campolmi, P | 2 |
| Reali, EF | 1 |
| Mori, M | 1 |
| Rossi, R | 2 |
| Weston, A | 1 |
| Fitzgerald, P | 1 |
| Vinciullo, C | 1 |
| Elliott, T | 1 |
| Francis, D | 1 |
| Spelman, L | 1 |
| Nguyen, R | 1 |
| Weightman, W | 1 |
| Sheridan, A | 1 |
| Reid, C | 1 |
| Czarnecki, D | 1 |
| Murrell, D | 1 |
| Thompson, MS | 2 |
| Johansson, A | 1 |
| Johansson, T | 2 |
| Svanberg, S | 7 |
| Garcia-Zuazaga, J | 1 |
| Cooper, KD | 1 |
| Kreutzer, K | 1 |
| Bonnekoh, B | 1 |
| Franke, I | 1 |
| Gollnick, H | 1 |
| Tan, SK | 1 |
| Cerio, R | 1 |
| Goldsmith, PC | 1 |
| McGregor, JM | 1 |
| Proby, CM | 1 |
| Harwood, CA | 1 |
| Breuninger, H | 1 |
| Angell-Petersen, E | 2 |
| Sørensen, R | 1 |
| Peng, Q | 4 |
| Giercksky, KE | 6 |
| Stenquist, B | 2 |
| Strandeberg, C | 1 |
| Mölne, L | 2 |
| Chapas, AM | 1 |
| Nestor, MS | 1 |
| Gold, MH | 1 |
| Kauvar, AN | 1 |
| Taub, AF | 1 |
| Geronemus, RG | 1 |
| Ritvo, EC | 1 |
| Goldman, MP | 1 |
| Gilbert, DJ | 1 |
| Richey, DF | 1 |
| Alster, TS | 1 |
| Bank, DE | 1 |
| Carruthers, A | 1 |
| Carruthers, J | 1 |
| Rigel, DS | 1 |
| Robins, P | 1 |
| Spencer, JM | 1 |
| Zelickson, BD | 1 |
| Shen, SC | 2 |
| Lee, WR | 1 |
| Fang, YP | 1 |
| Hu, CH | 1 |
| Fang, JY | 1 |
| Caty, V | 1 |
| Liu, Y | 1 |
| Viau, G | 1 |
| Kapostins, J | 1 |
| Stenram, U | 2 |
| Spigulis, J | 1 |
| Pavel, S | 1 |
| Stender, I | 1 |
| Bakker-Wensveen, CA | 1 |
| Lane, JE | 1 |
| Allen, JH | 1 |
| Lane, TN | 1 |
| Lesher, JL | 1 |
| Misra, A | 1 |
| Maybury, K | 1 |
| Eltigani, TA | 1 |
| Woods, J | 1 |
| Brancaleon, L | 2 |
| Goodman, C | 1 |
| Kruijt, B | 1 |
| Martino Neumann, HA | 1 |
| Skiveren, J | 1 |
| Philipsen, PA | 1 |
| Star, WM | 1 |
| van't Veen, AJ | 1 |
| Munte, K | 1 |
| Annemans, L | 1 |
| Lambert, J | 1 |
| Roelandts, R | 2 |
| Blume, JE | 1 |
| Ghaffar, SA | 1 |
| Clements, SE | 1 |
| Braathen, LR | 1 |
| Pariser, D | 1 |
| Won, Y | 1 |
| Hong, SH | 1 |
| Yu, HY | 1 |
| Kwon, YH | 1 |
| Yun, SJ | 1 |
| Lee, SC | 1 |
| Lee, JB | 1 |
| de Rie, MA | 1 |
| Leifsdottir, R | 1 |
| Yu, RC | 1 |
| Bachmann, I | 1 |
| Richard, MA | 1 |
| Anstey, A | 1 |
| Brownell, I | 1 |
| Matthew, J | 1 |
| Vaschieri, C | 1 |
| Marconi, A | 1 |
| Giannetti, A | 1 |
| Pincelli, C | 1 |
| Moussa, G | 1 |
| Altmeyer, P | 1 |
| Lesar, AE | 1 |
| Fijan, S | 1 |
| Hönigsmann, H | 1 |
| Ortel, B | 1 |
| Roberts, DJ | 2 |
| Cairnduff, F | 3 |
| Hohenleutner, U | 2 |
| Heine, A | 1 |
| Orenstein, A | 2 |
| Kostenich, G | 2 |
| Tsur, H | 1 |
| Kogan, L | 1 |
| Malik, Z | 2 |
| Lang, S | 1 |
| Baumgartner, R | 1 |
| Struck, R | 1 |
| Leunig, A | 1 |
| Gutmann, R | 1 |
| Feyh, J | 1 |
| Lui, H | 1 |
| Salasche, S | 1 |
| Kollias, N | 2 |
| Wimberly, J | 1 |
| Flotte, T | 1 |
| McLean, D | 1 |
| Hoerauf, H | 1 |
| Hüttmann, G | 1 |
| Diddens, H | 1 |
| Thiele, B | 1 |
| Laqua, H | 1 |
| Andersson, T | 1 |
| Killander, D | 1 |
| Wang, I | 6 |
| Berg, R | 2 |
| Johansson, J | 1 |
| Stringer, MR | 2 |
| Hudson, EJ | 1 |
| Ash, DV | 1 |
| Sassy, T | 1 |
| Rieger, E | 1 |
| Kerl, H | 3 |
| Martin, A | 2 |
| Grevelink, JM | 1 |
| Starr, JC | 1 |
| Fewkes, JL | 1 |
| Flotte, TJ | 1 |
| Deutsch, TF | 1 |
| Heyerdahl, H | 2 |
| Steen, HB | 2 |
| Nesland, JM | 2 |
| Becker-Wegerich, PM | 1 |
| Schulte, KW | 3 |
| Neuse, W | 1 |
| Goerz, G | 4 |
| Verwohlt, B | 1 |
| Bolsen, K | 3 |
| Lindholm, LE | 1 |
| Alpsten, M | 1 |
| Balas, CJ | 1 |
| Stefanidou, MP | 1 |
| Katsantonis, JC | 1 |
| Georgiou, SK | 1 |
| Tzardi, MN | 1 |
| Liu, DL | 1 |
| Nilsson, GE | 1 |
| Wårdell, K | 1 |
| Batz, J | 1 |
| Zumdick, M | 1 |
| Fink-Puches, R | 2 |
| Revenga Arranz, F | 1 |
| MacKie, RM | 2 |
| Whitehurst, C | 3 |
| Moore, JV | 2 |
| McColl, JH | 2 |
| Ross, EV | 1 |
| Gillies, R | 1 |
| Soyer, HP | 1 |
| Hofer, A | 1 |
| Harth, Y | 2 |
| Hirshowitz, B | 1 |
| Kaplan, B | 1 |
| Hürlimann, AF | 1 |
| Hänggi, G | 1 |
| Panizzon, RG | 1 |
| Ternesten, A | 1 |
| Stahl, W | 1 |
| Blohm, E | 1 |
| Lang, K | 2 |
| Sies, H | 1 |
| Bauer, B | 1 |
| Tausjø, J | 3 |
| Berner, A | 2 |
| af Klinteberg, C | 2 |
| Enejder, AM | 1 |
| Ninomiya, Y | 2 |
| Itoh, Y | 2 |
| Henta, T | 2 |
| Ishibashi, A | 2 |
| Canti, G | 1 |
| Cubeddu, R | 1 |
| Eker, C | 1 |
| Pifferi, A | 1 |
| Taroni, P | 1 |
| Valentini, G | 1 |
| Tajima, S | 1 |
| Hirshovitz, B | 1 |
| Lönnroth, P | 1 |
| Larson, G | 1 |
| Haller, JC | 1 |
| Slack, G | 1 |
| Schofield, J | 1 |
| Tunstall, R | 1 |
| Ackermann, G | 1 |
| Abels, C | 1 |
| Bäumler, W | 1 |
| Haddad, R | 1 |
| Cohen, M | 1 |
| Kaplan, O | 1 |
| Greenberg, R | 1 |
| Kashtan, H | 1 |
| Hewett, J | 1 |
| Nadeau, V | 1 |
| Allen, JW | 1 |
| Sibbett, W | 1 |
| Padgett, M | 1 |
| Jee, SH | 1 |
| Chiu, HC | 1 |
| Tsai, WL | 1 |
| Kuo, ML | 1 |
| Langmack, K | 2 |
| Mehta, R | 1 |
| Twyman, P | 1 |
| Norris, P | 1 |
| Fischer, F | 1 |
| Dickson, EF | 1 |
| Kennedy, JC | 2 |
| Pottier, RH | 2 |
| Dijkstra, AT | 1 |
| Majoie, IM | 1 |
| van Dongen, JW | 1 |
| van Weelden, H | 1 |
| van Vloten, WA | 1 |
| Collins, S | 1 |
| Jenkinson, H | 1 |
| Kurwa, H | 1 |
| Pearse, AD | 1 |
| Stringer, M | 1 |
| Taylor, DK | 1 |
| Wong, G | 1 |
| Pross, DC | 1 |
| el-Sharabasy, MM | 1 |
| Hegazy, AA | 1 |
| el-Soubky, MS | 1 |
| el-Maksoud, MA | 1 |
| Zhou, Q | 1 |
| Wang, B | 1 |
| Keyal, U | 1 |
| Bhatta, AK | 1 |
| Qidwai, A | 1 |
| Khan, S | 1 |
| Md, S | 1 |
| Fazil, M | 1 |
| Baboota, S | 1 |
| Narang, JK | 1 |
| Ali, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)[NCT02144077] | Phase 3 | 281 participants (Actual) | Interventional | 2014-01-28 | Completed | ||
| Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease: a Multicenter Randomized Controlled Trial[NCT03909646] | Phase 4 | 250 participants (Anticipated) | Interventional | 2019-05-27 | Recruiting | ||
| Fluorescence and Thermal Imaging of the Skin Before and During Photodynamic Therapy[NCT03167762] | 18 participants (Actual) | Interventional | 2017-06-22 | Completed | |||
| Dimethylsulphoxide-supported Photodynamic Therapy of Basal Cell Carcinoma Combined With Curettage - A 6 Year Clinical and Histological Evaluation.[NCT00218829] | 44 participants (Actual) | Observational | 1997-09-30 | Completed | |||
| A Randomized Assessor-blinded Comparison of Low Irradiance and Conventional Irradiance Photodynamic Therapy (PDT) for Superficial Non-melanoma Skin Cancer[NCT02872909] | 50 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| A Randomized Half-side Comparative Trial of Fractional Laser-assisted Daylight Photodynamic Therapy Versus Daylight Photodynamic Therapy in Organ Transplant Recipients With Multiple Actinic Keratoses of the Scalp or Forehead[NCT01898936] | 12 participants (Actual) | Interventional | 2013-08-31 | Completed | |||
| Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients[NCT01538901] | Phase 4 | 10 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to prolonged recruitment phase) | ||
| Interferon Alpha Therapy for Cervical CIN I and HPV Infection[NCT06137950] | Phase 1 | 90 participants (Anticipated) | Interventional | 2023-11-07 | Recruiting | ||
| Evaluation of the Formulation of 5-aminolevulinic Acid With Dimethylsulfoxide in Photodynamic Therapy for Treatment of Actinic Keratosis[NCT01459393] | Phase 3 | 137 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ[NCT03025724] | 40 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Lesion complete response (completely cleared individual lesions) assessed 12 weeks after the last PDT. The indicated values give percentage of overall completely cleared individual lesions. The PP set is the primary analysis set for the analysis of the secondary endpoint. (NCT02144077)
Timeframe: 12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
| Intervention | Percentage of Individual Lesions (Number) |
|---|---|
| BF-200 ALA | 94.6 |
| Methyl-aminolevulinate | 92.9 |
Overall patient complete response rate assessed 12 weeks after the last PDT. The indicated values give the percentage of overall complete responders. An overall complete responder is defined as a patient in whom all treated lesions were cleared. The PP set is the primary analysis set for the analyses of the primary endpoint. (NCT02144077)
Timeframe: 12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
| Intervention | Percentage of Patients (Number) |
|---|---|
| BF-200 ALA | 93.4 |
| Methyl-aminolevulinate | 91.8 |
Patient complete response (complete clearance of all treated lesions) assessed 12 weeks after PDT-2 (first PDT cycle). The PP set is the primary analysis set for the analysis of the secondary endpoint. (NCT02144077)
Timeframe: 12 weeks after PDT-2 (=PDT cycle 1; please note: in this study 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
| Intervention | Percentage of Patients (Number) |
|---|---|
| BF-200 ALA | 57.9 |
| Methyl-aminolevulinate | 56.4 |
Patient recurrence rate defined as the number of patients with at least one recurrent lesion during FU after complete clearance 12 weeks after the last PDT (NCT02144077)
Timeframe: 6, 12, 24, 36 and 60 months post-PDT
| Intervention | percentage of patients (cumulative) (Number) |
|---|---|
| BF-200 ALA | 16.9 |
| Methyl-aminolevulinate | 15.5 |
"Reduction of total lesion area (summation of sizes of all treated lesions) per patient, assessed 12 weeks after the last PDT. The PP set is the primary analysis set for the analysis of the secondary endpoint.~Please note that the high SD for BF-200 ALA is due to a patient who had increased lesion area fom 63 mm² at baseline to 225 mm² 12 weeks after PDT. This lesion area included a lesion that was later confirmed to be benign skin condition (lentigo solaris)." (NCT02144077)
Timeframe: 12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
| Intervention | Percentage of Change (Mean) |
|---|---|
| BF-200 ALA | -94.5 |
| Methyl-aminolevulinate | -97.0 |
"Overall cosmetic outcome 12 weeks after last PDT is calculated as difference between 12 weeks after PDT sum score and baseline sum score of all skin quality assessments. Each of the below skin quality characteristics are assessed on a 4-point scale from 0 (none) to 3 (severe) by the investigator at baseline and 12 weeks after last PDT:~Skin surface~Hyperpigmentation~Hypopigmentation~Mottled or irregular pigmentation~Degree of scarring~Atrophy~Cosmetic outcome categories are:~Very good: 12 weeks sum score improved by at least 2 points compared to baseline~Good: 12 weeks sum score improved by 1 point compared to baseline~Satisfactory: 12 weeks sum score identical to the one at baseline~Unsatisfactory: 12 weeks sum score worsened by 1 point compared to baseline~Impaired: 12 weeks sum score worsened by at least 2 points compared to baseline" (NCT02144077)
Timeframe: 12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
| Intervention | Percentage of Patients (Number) | ||||
|---|---|---|---|---|---|
| Very good | Good | Satisfactory | Unsatisfactory | Impaired | |
| BF-200 ALA | 23.3 | 11.7 | 35.8 | 14.2 | 15.0 |
| Methyl-aminolevulinate | 14.7 | 18.3 | 29.4 | 20.2 | 17.4 |
"Overall cosmetic outcome 12 weeks after last PDT is calculated as difference between 12 weeks after PDT sum score and baseline sum score of all skin quality assessments. Each of the below skin quality characteristics are assessed on a 4-point scale from 0 (none) to 3 (severe) by the investigator at baseline and 12 weeks after last PDT:~Skin surface~Hyperpigmentation~Hypopigmentation~Mottled or irregular pigmentation~Degree of scarring~Atrophy~Cosmetic outcome categories are:~Very good: 12 weeks sum score improved by at least 2 points compared to baseline~Good: 12 weeks sum score improved by 1 point compared to baseline~Satisfactory: 12 weeks sum score identical to the one at baseline~Unsatisfactory: 12 weeks sum score worsened by 1 point compared to baseline~Impaired: 12 weeks sum score worsened by at least 2 points compared to baseline" (NCT02144077)
Timeframe: 12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
| Intervention | Percentage of Patients (Number) | ||||
|---|---|---|---|---|---|
| Very good | Good | Satisfactory | Unsatisfactory | Impaired | |
| BF-200 ALA | 40.0 | 20.0 | 22.9 | 11.4 | 5.7 |
| Methyl-aminolevulinate | 21.6 | 27.0 | 32.4 | 12.2 | 6.8 |
Lesion recurrence rate defined as the number of completely cleared lesions 12 weeks after the last PDT showing recurrence during FU. Overall and subgroup analysis (nodular basal cell carcinoma (nBCC) and superficial basal cell carcinoma (sBCC)). (NCT02144077)
Timeframe: 6, 12, 24, 36 and 60 months post-PDT
| Intervention | percentage of lesions (cumulative) (Number) | ||
|---|---|---|---|
| Overall | sBCC | nBCC | |
| BF-200 ALA | 13.5 | 10.3 | 25 |
| Methyl-aminolevulinate | 13.4 | 11.9 | 21.4 |
clinical assessment by study dermatologist to determine by inspection and palpation whether the lesion is clear, partially clear or not clear - assessed at 3, 6 and 12 months after treatment, with 12 months as the final study outcome endpoint analysed (NCT02872909)
Timeframe: 12 months after treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Irradiance LED PDT | 27 |
| Conventional Higher Irradiance LED | 14 |
assess on visual analogue scale (VAS) score of 0 - 10cm, with 0 representing no pain experienced through to 10 representing the worst pain imaginable. The participant marks across a 0-10cm unmarked line where their level of pain experience is and this is measured eg. 2cm if experiencing mild pain or 8.5cm which would represent severe pain (NCT02872909)
Timeframe: one week after treatment
| Intervention | score on a scale (Median) |
|---|---|
| Low Irradiance LED PDT | 2.95 |
| Conventional Higher Irradiance LED | 1.25 |
"brief patient questionnaire to evaluate their opinion of the treatment they received. This is assessed as A.efficacy of treatment - 1 = not effective NR; 2 = partIally effective PR; 3 = completely effective CR; B.Side effects of treatment eg. pain and inflammation - 1 = severe; 2 = moderate; 3 = mild; 4 = none/minimal. C.Practicalities of treatment eg. ease of use, travel, time, inconvenience - 1 = very disruptive and difficult; 2 = moderately disruptive and difficult; 3 = minimally disruptive and difficult. The scores of A, B and C will be added to give an overall score with range of overall minimum score option 3 and maximum 10.~Patients will also separately be asked to give overall evaluation on a VAS scale of 0 = treatment very poor and would not have again through to 10 = treatment excellent and I would have again - with a continuous line option from 0 - 10 to mark across, providing a separate score with range options 0 to 10" (NCT02872909)
Timeframe: one year after treatment - last visit
| Intervention | score on a scale (Median) |
|---|---|
| Low Irradiance LED PDT | 10 |
| Conventional Higher Irradiance LED | 10 |
"erythema, oedema, blistering, crusting, ulceration on semi-quantitative scale. Erythema is graded as 0 = absent, 1 = mild, 2 = moderate or 3 = severe erythema as assessed by naked eye examination. Oedema is graded as 0 = absent or 1 = present. Likewise crusting or ulceration are each graded as 0 = absent and 1 = present by naked eye examination. Data will be presented and analysed separately ie. erythema data will be presented and then separately whether oedema, crusting or ulceration are present or absent.~ie. reporting may appear as example: erythema score 3 of range of 0-3 options; oedema score 1 (binary option of 0 or 1); crusting score 0 (binary option of 0 or 1); ulceration score 0 (binary option of 0 or 1)" (NCT02872909)
Timeframe: one week after treatment
| Intervention | score on a scale (Median) |
|---|---|
| Low Irradiance LED PDT | 2 |
| Conventional Higher Irradiance LED | 1 |
40 reviews available for aminolevulinic acid and Carcinoma, Basal Cell, Pigmented
| Article | Year |
|---|---|
Photodynamic therapy with methyl-5-aminolevulinate for basal cell carcinoma: A systematic review and meta-analysis.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensitizing Agents; Skin | 2020 |
Photodynamic therapy in dermatology: Beyond current indications.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Dermatology; Humans; Keratosis, Actinic; Photochemothera | 2020 |
Daylight Photodynamic Therapy: An Update.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Bowen's Disease; Carcinoma, Basal Cell; Cheilit | 2020 |
Interventions for basal cell carcinoma of the skin.
Topics: Adult; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Basal Cell; Cryotherapy; Female; Human | 2020 |
Nanocarriers for Photodynamic Therapy Intended to Cutaneous Tumors.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Drug Carriers; Humans; Nanoparticles; P | 2021 |
An update on topical photodynamic therapy for clinical dermatologists.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Dermatologists; Humans; Light; | 2019 |
Photodynamic therapy in the treatment of basal cell carcinoma.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Skin Neoplasms | 2013 |
[PDT panoramic view. Principle, photosensitizers, light sources and validated indications in dermatology].
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Clinical Trials as Topic; Humans; Kerat | 2013 |
Usefulness of Photodynamic Therapy as a Possible Therapeutic Alternative in the Treatment of Basal Cell Carcinoma.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Neoplasm Staging; Photochemotherapy; Skin Neopla | 2015 |
Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Neoplasm Recurrence, Local; Photochemotherapy; P | 2016 |
Intralesional agents in the management of cutaneous malignancy: a review.
Topics: Aminolevulinic Acid; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bleomycin; Carci | 2011 |
Nonmelanoma skin cancer chemoprevention.
Topics: Acitretin; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carc | 2011 |
Photodynamic therapy: current evidence and applications in dermatology.
Topics: Acne Vulgaris; Aminolevulinic Acid; Bowen's Disease; Candidiasis; Carcinoma, Basal Cell; Humans; Ker | 2011 |
[Fluorescence diagnosis of non-melanoma skin cancer].
Topics: Aminolevulinic Acid; Apoptosis; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous | 2012 |
Photodynamic therapy for nonmelanoma skin cancers. Current review and update.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dihematoporph | 2003 |
The role of light in the treatment of non-melanoma skin cancer using methyl aminolevulinate.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Photochemotherapy; Ski | 2003 |
Clinical efficacy of methyl aminolevulinate (Metvix) photodynamic therapy.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials, Phase III as | 2003 |
Methyl aminolevulinate (Metvix) photodynamic therapy - practical pearls.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Photochemotherapy; Pra | 2003 |
A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Basal Cell; Clinical Trials as Topic; Humans; Ker | 2004 |
Topical methyl aminolevulinate.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratosis; Photochemo | 2004 |
delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome.
Topics: Adult; Aminolevulinic Acid; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Female; Humans; Middle | 2004 |
Topical photodynamic therapy in clinical dermatology.
Topics: Adult; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratosis; Phot | 2004 |
[The wider application of photodynamic therapy in dermatology].
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Dermatology; Humans; Keratosis; Photoch | 2005 |
Clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma and solar keratosis.
Topics: Adult; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratosis; Photochemotherapy; Photosensit | 2005 |
Photodynamic therapy in dermatology: current concepts in the treatment of skin cancer.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Clinical Trials as Topic; Humans; Keratosis; Photochemot | 2005 |
Aminolevulinic acid photodynamic therapy for skin cancers.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Photo | 2007 |
Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensitizing Agents; Skin | 2007 |
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005.
Topics: Aminolevulinic Acid; Australia; Basal Cell Nevus Syndrome; Bowen's Disease; Carcinoma, Basal Cell; C | 2007 |
Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis; Photochemotherapy; P | 2007 |
Photodynamic therapy of primary skin cancer: a review.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Agents; Bowen's Disease; Carcinoma, Basal Cell; Female; Fo | 1995 |
Photodynamic therapy of superficial basal cell carcinoma by instillation of aminolevulinic acid and irradiation with visible light.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Injections, Intralesional; Male; Middle Aged; Ph | 1997 |
[Medical treatment of epitheliomas].
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Bowen's Disease; Carcinoma; Car | 1997 |
Photodynamic therapy in dermatology.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cel | 1998 |
Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Human | 1999 |
Basal cell carcinoma--new aspects of diagnosis and treatment.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Interferons; Laser-Doppler Flowmetry; Microdialy | 2000 |
Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy.
Topics: Aged; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinica | 2001 |
Topical 5-aminolevulinic acid and photodynamic therapy in dermatology: a minireview.
Topics: Administration, Topical; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Clinical Trial | 2001 |
Aminolevulinic acid: pharmacological profile and clinical indication.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Clinical Trials as Topic; Drug Evaluation; Humans; Photo | 2001 |
Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Health Care Costs; Humans; Keratosis; L | 2002 |
The emerging role of 5-ALA-PDT in dermatology: is PDT superior to standard treatments?
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis; Photochemotherapy; P | 2002 |
74 trials available for aminolevulinic acid and Carcinoma, Basal Cell, Pigmented
| Article | Year |
|---|---|
A randomized assessor-blinded comparison of low-irradiance and conventional-irradiance photodynamic therapy for superficial basal cell carcinoma and Bowen disease.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensiti | 2022 |
Long-Term Efficacy of Photodynamic Therapy with Fractionated 5-Aminolevulinic Acid 20% versus Conventional Two-Stage Topical Methyl Aminolevulinate for Superficial Basal-Cell Carcinoma.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensitizing Agents; Sing | 2022 |
Hexyl aminolevulinate, 5-aminolevulinic acid nanoemulsion and methyl aminolevulinate in photodynamic therapy of non-aggressive basal cell carcinomas: A non-sponsored, randomized, prospective and double-blinded trial.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensitizing Agents; Pros | 2020 |
Treatment of superficial basal cell carcinoma with 7.8% 5-aminolaevulinic acid nanoemulsion-based gel (BF-200 ALA) and photodynamic therapy: Results in clinical practice in a tertiary hospital.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Middle Aged; Photochemotherapy; Ph | 2021 |
Patient preferences for the attributes of a noninvasive treatment for superficial basal cell carcinoma: a discrete choice experiment.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Choice Behavior; Dermatologic Agents; Drug Therapy, Comb | 2018 |
Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolaevulinic acid 20% vs. two-stage topical methyl aminolaevulinate: results of a randomized controlled trial.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cel | 2018 |
Combination vismodegib and photodynamic therapy for multiple basal cell carcinomas.
Topics: Aged; Aminolevulinic Acid; Anilides; Antineoplastic Agents; Carcinoma, Basal Cell; Combined Modality | 2018 |
A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; M | 2018 |
Blue light versus red light for photodynamic therapy of basal cell carcinoma in patients with Gorlin syndrome: A bilaterally controlled comparison study.
Topics: Adult; Aminolevulinic Acid; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Female; Humans; Light; | 2018 |
Short incubation fractional CO
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Carc | 2019 |
Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therap | 2013 |
Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Antim | 2013 |
Optical coherence tomography imaging of non-melanoma skin cancer undergoing photodynamic therapy reveals subclinical residual lesions.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Keratosi | 2014 |
Experience and BCC subtypes as determinants of MAL-PDT response: preliminary results of a national Brazilian project.
Topics: Aminolevulinic Acid; Brazil; Carcinoma, Basal Cell; Female; Humans; Male; Photochemotherapy; Photose | 2014 |
Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Combined Chemotherap | 2014 |
Novel photodynamic therapy does not prevent new skin cancers--randomized controlled trial.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Facial Neoplasms; Female | 2014 |
Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas--a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therap | 2015 |
Effect of methylene blue-mediated photodynamic therapy for treatment of basal cell carcinoma.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Methylene Blue; Middl | 2015 |
Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Ant | 2015 |
Development of a handheld fluorescence imaging device to investigate the characteristics of protoporphyrin IX fluorescence in healthy and diseased skin.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Optical Imaging; Photosensit | 2015 |
Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studies; Humans; Lasers, Solid-S | 2016 |
Preliminary results of comparative study for subsequent photodynamic therapy versus secondary excision after primary excision for treating basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Disease-Free Survival; F | 2017 |
Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Dose-Response Relationsh | 2008 |
A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; | 2008 |
Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Middle Aged; Net | 2008 |
Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Facia | 2010 |
Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes.
Topics: Aged; Aminolevulinic Acid; Belgium; Carcinoma, Basal Cell; Female; Humans; Male; Middle Aged; Photoc | 2009 |
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studie | 2009 |
PpIX fluorescence combined with auto-fluorescence is more accurate than PpIX fluorescence alone in fluorescence detection of non-melanoma skin cancer: an intra-patient direct comparison study.
Topics: Aminolevulinic Acid; Biomarkers, Tumor; Bowen's Disease; Carcinoma; Carcinoma, Basal Cell; False Neg | 2012 |
Topical photodynamic therapy significantly reduces epidermal Langerhans cells during clinical treatment of basal cell carcinoma.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Langerh | 2012 |
The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Middle Aged; Neoplasm Recurr | 2012 |
Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Oxygen; Pho | 2013 |
Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cel | 2012 |
The time-dependent accumulation of protoporphyrin IX fluorescence in nodular basal cell carcinoma following application of methyl aminolevulinate with an oxygen pressure injection device.
Topics: Aminolevulinic Acid; Biological Transport; Carcinoma, Basal Cell; Injections; Oxygen; Photosensitizi | 2012 |
Fluorescence contrast and threshold limit: implications for photodynamic diagnosis of basal cell carcinoma.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Facial Neoplasms; Humans; Image | 2003 |
The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Car | 2003 |
Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; | 2003 |
Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; | 2004 |
A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studies; Heart Transplant | 2004 |
A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studies; Heart Transplant | 2004 |
A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studies; Heart Transplant | 2004 |
A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studies; Heart Transplant | 2004 |
New proposal for the treatment of nodular basal cell carcinoma with intralesional 5-aminolevulinic acid.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Injections, Intralesional; | 2004 |
Clinical system for interstitial photodynamic therapy with combined on-line dosimetry measurements.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Computer Systems; Equipment Design; Equipment Failure An | 2005 |
[Photodynamic therapy with methylaminooxopentanoate (Metvix) and a broad band light source (PhotoDyn 501): practical experiences in problem-patients with actinic keratoses and basal cell carcinomas].
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Keratosis; Ligh | 2004 |
Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate.
Topics: Administration, Topical; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Double-Blind Method; Fema | 2006 |
Photodynamic therapy of nodular basal cell carcinoma with multifiber contact light delivery.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Fluorescence; Humans; Lasers; Male; | 2006 |
Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients.
Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Im | 2006 |
Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Darkness; Humans; Light; | 2006 |
Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Double-Blind Method; Gel | 2006 |
Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Fluorescence; Humans; M | 2006 |
Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma.
Topics: Aminolevulinic Acid; Belgium; Carcinoma, Basal Cell; Cost-Benefit Analysis; Cryosurgery; Decision Ma | 2006 |
Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female | 2007 |
A clinical investigation to determine the effect of pressure injection on the penetration of topical methyl aminolevulinate into nodular basal cell carcinoma of the skin.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Drug Delivery Systems; Humans; Injections, Intralesional | 2007 |
Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Cell Line, Tumor; Humans; In Vi | 2008 |
Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Follow-Up Studies; Head | 2008 |
Does surface preparation alter ALA uptake in superficial non-melanoma skin cancer in vivo?
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Cure | 2008 |
Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; | 1995 |
Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer.
Topics: Adenocarcinoma; Administration, Topical; Aminolevulinic Acid; Bowen's Disease; Breast Neoplasms; Car | 1994 |
Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment.
Topics: Administration, Cutaneous; Adult; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; | 1995 |
Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cel | 1996 |
Superficial blood flow following photodynamic therapy of malignant non-melanoma skin tumours measured by laser Doppler perfusion imaging.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Female; | 1997 |
Protoporphyrin IX fluorescence induced in basal cell carcinoma by oral delta-aminolevulinic acid.
Topics: Administration, Oral; Aminolevulinic Acid; Carcinoma, Basal Cell; Drug Interactions; Fluorescence; H | 1998 |
Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Carcin | 1998 |
Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma, Bas | 1998 |
In vivo detection of basal cell carcinoma using imaging spectroscopy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma, Basal Ce | 1999 |
Kinetic fluorescence studies of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation in basal cell carcinomas.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; | 1999 |
Preliminary evaluation of two fluorescence imaging methods for the detection and the delineation of basal cell carcinomas of the skin.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Male; Photosensi | 2000 |
Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Dimethyl Sulfoxide; Edetic Acid; Female; Humans; Light; | 2000 |
[Topical photodynamic therapy in basal and squamous cell carcinoma and penile Bowen's disease with 20% aminolevulinic acid, and exposure to red light and infrared light].
Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; C | 1998 |
Photodynamic therapy of residual or recurrent basal cell carcinoma after radiotherapy using topical 5-aminolevulinic acid or methylester aminolevulinic acid.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female | 2000 |
Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Follow-Up Studies; Huma | 2000 |
[Photodynamic therapy of nasal basal cell carcinoma].
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; | 2001 |
Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Female; | 2001 |
Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Analysis of Variance; Carcino | 2001 |
Photodynamic therapy with violet light and topical 6-aminolaevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carci | 2001 |
Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratosis; Ph | 1990 |
190 other studies available for aminolevulinic acid and Carcinoma, Basal Cell, Pigmented
| Article | Year |
|---|---|
Bimodal photodynamic therapy for treatment of a 91-year-old patient with locally advanced cutaneous basal cell carcinoma and postoperative scar management.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Cicatrix; Humans; Photochemothe | 2021 |
A new photodynamic therapy protocol for nodular basal cell carcinoma treatment: Effectiveness and long-term follow-up.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Follow-Up Studies; Humans; Photochemotherapy; Phot | 2022 |
Photodynamic therapy for superficial basal cell carcinomas: Clinical features of partial responses and recurrences.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Recurrence; Skin Neoplasms; T | 2022 |
In vitro 5-Fluorouracil resistance produces enhanced photodynamic therapy damage in SCC and tumor resistance in BCC.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; | 2022 |
Surgery combined with photodynamic therapy versus surgery alone for the treatment of non-melanoma skin cancer and actinic keratosis: A retrospective cohort study.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Keratosis, Actinic; Photochemotherapy; P | 2022 |
A 10-year follow-up on the chemopreventive role of photodynamic therapy in a Gorlin syndrome patient.
Topics: Aminolevulinic Acid; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Follow-Up Studies; Humans; Ph | 2022 |
Intralesional photodynamic therapy induces apoptosis in basal cell carcinoma and Bowen's disease through caspase 3 and granzyme B.
Topics: Aminolevulinic Acid; Apoptosis; bcl-2-Associated X Protein; Bowen's Disease; Carcinoma, Basal Cell; | 2023 |
Non-Invasive Treatment of Basal Cell Carcinoma: Photodynamic Therapy Following Curettage.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Curettage; Female; Humans; Male; Middle Aged; Ontario; P | 2023 |
Photodynamic therapy for basal cell carcinoma of external auditory canal: A case report.
Topics: Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Ear Canal; Female; Humans; Lasers, Se | 2019 |
Comment on "Photodynamic therapy in the treatment of basal cell carcinoma: A systematic review and meta-analysis".
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensitizing Agents; Skin | 2019 |
A safe and effective treatment: Surgery combined with photodynamic therapy for multiple basal cell carcinomas.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Hamartoma Syndrome, Multiple; | 2019 |
An audit of pain scores with conventional and white light topical 5-methyl aminolaevulinic acid photodynamic therapy for superficial basal cell carcinoma and squamous cell carcinoma in situ.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Femal | 2020 |
Combined CO
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Fema | 2019 |
Optical coherence angiography for pre-treatment assessment and treatment monitoring following photodynamic therapy: a basal cell carcinoma patient study.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Angiography; Carcinoma, Basal Cell; Cohort Studies; Fa | 2019 |
Sequential Treatment of Superficial Basal Cell Carcinomas With Topical Methyl Aminolevulinate Photodynamic Therapy and Imiquimod 5% Cream: A Retrospective Study of Clinical and Cosmetic Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Topical 5-aminolevulinic acid-mediated photodynamic therapy for basal cell carcinoma.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Phot | 2020 |
Photodynamic therapy in combination with surgery for the treatment of an extensive squamous cell carcinoma in situ - A case report.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Neopl | 2020 |
[Photodynamic therapy of a giant basal cell carcinoma in a 71-year-old woman].
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Photochemotherapy; Photosensitizin | 2020 |
Lesion compression during light activation may improve efficacy of photodynamic treatment of basal cell carcinoma: preliminary results and rationale.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensitizing Agents; Skin | 2020 |
Monitoring PDT effects in basal cell carcinoma treatment using thermal imaging.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Male; Photochemotherapy; Photosensitizing Agents | 2020 |
Photodynamic diagnosis and photodynamic therapy in basal cell carcinoma using a novel laser light source.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Laser Therapy; Lasers; Photochemotherapy; Photos | 2020 |
5-aminolevulinic acid photodynamic therapy and excision surgery for nevoid basal cell carcinoma syndrome with multiple basal cell carcinomas and PTCH1 mutation.
Topics: Aminolevulinic Acid; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Hamartoma Syndrome, Multiple; | 2020 |
Clinical efficacy of Mohs surgery combined with topical photodynamic therapy for facial basal cell carcinoma.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Facial Neoplasms | 2020 |
Photodynamic therapy with 5-aminolevulinate patch for the treatment of superficial basal cell carcinomas.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensitizing Agents; Skin | 2020 |
Photodynamic therapy as a treatment option for multiple pigmented basal cell carcinoma: Long-term follow-up results.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; P | 2021 |
Methyl aminolevulinate photodynamic therapy after partial debulking in the treatment of superficial and nodular basal cell carcinoma: 3-years follow-up.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Cytoreduction Surgical Procedures; Follow-Up Studi | 2021 |
Comparative histological and immunohistochemical changes in recurrent nodular basal cell carcinoma after photodynamic therapy.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Neoplasm Recurrence, Local; Photochemotherapy; P | 2021 |
Treatment of cutaneous basal cell carcinoma with combined laser extirpation and methyl aminolevulinic acid: five-year success rates.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therap | 2021 |
Combination curettage and modified ALA-PDT for multiple basal cell carcinomas of the face and head.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Curettage; Hamartoma Syndrome, Multiple; Humans; Neoplas | 2021 |
Photodynamic therapy effective for the treatment of actinic keratosis and basal cell carcinoma in bullous pemphigoid patients.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Dose-Response Relations | 2017 |
Methyl aminolevulinate photodynamic therapy combined with curettage debulking for pigmented basal cell carcinoma.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Middle Ag | 2017 |
Photodynamic therapy with epidermal ablation using fractional CO
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Asian People; Carcinoma, Basal Cell; Combined Modality | 2017 |
Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cel | 2018 |
Effect of light polarization on the efficiency of photodynamic therapy of basal cell carcinomas: an in vitro cellular study.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Cell Line, Tumor; Cell Survival; Humans; Light; Photoche | 2018 |
New combination strategy of photodynamic therapy and surgery in treating recurrent basal cell carcinoma, a case report.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Male; Middle Aged; Mohs Surgery; Neoplasm Recurr | 2018 |
Comparison of treatment of basal cell carcinoma between surgery and intralesional photodynamic therapy: A cross-sectional study.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Cross-Sectional Studies; Female | 2018 |
Comparing Topical Treatments for Basal Cell Carcinoma.
Topics: Aminolevulinic Acid; Aminoquinolines; Carcinoma, Basal Cell; Fluorouracil; Humans; Imiquimod; Neopla | 2018 |
Inflammatory response and cytokine levels induced by intralesional photodynamic therapy and 630-nm laser in a case series of basal cell carcinoma.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Cyto | 2018 |
Optimizing photodynamic therapy regimens: variables in irradiation may influence outcomes.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensitizing Agents; Skin | 2018 |
Cells to Surgery Quiz: July 2018.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Basal Cell; Diseas | 2018 |
Factors influencing pain and efficacy of topical photodynamic therapy: a retrospective study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Car | 2019 |
Shedding light on photodynamic therapy for basal cell carcinoma.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Skin Neoplasms | 2018 |
Curettage and multiple needle puncture-assisted methyl-aminolaevulinate photodynamic therapy of basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Curettage; Female; Human | 2018 |
Histologic subtype of treatment failures after noninvasive therapy for superficial basal cell carcinoma: An observational study.
Topics: Aged; Aminolevulinic Acid; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Basal | 2019 |
Treatment of superficial basal cell carcinoma with photodynamic therapy. Observational study in 22 patients with 5-aminolaevulinic acid and methyl aminolaevulinate.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Photochemotherapy; Photosens | 2019 |
Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Animals; Biomarkers, Tumor; Carcinoma, Basal Cell; Cel | 2019 |
Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Eye; | 2019 |
Combined carbon dioxide laser with photodynamic therapy for nodular and superficial basal cell carcinoma.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Female; Follow-Up Studi | 2014 |
Risk of acute postoperative hypertension after topical photodynamic therapy for non-melanoma skin cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Aminolevulinic Acid; Blood Pressure; Bowen's Disease; Carcinom | 2013 |
Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy.
Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Basal Cell Nevus Syndrome; Carcinoma, Bas | 2014 |
Treating basal-cell carcinoma in a real life setting.
Topics: Aminolevulinic Acid; Aminoquinolines; Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Imiquimod | 2013 |
Fractional carbon dioxide laser improves nodular basal cell carcinoma treatment with photodynamic therapy with methyl 5-aminolevulinate.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Female; Humans; Lasers, Gas; | 2013 |
5-aminolevulinic acid based photodynamic therapy for basal cell carcinoma: a 10-years follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studie | 2013 |
Effect of pigmentation on photodynamic therapy.
Topics: Aminolevulinic Acid; Aminoquinolines; Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Male; Pho | 2013 |
Effect of pigmentation on photodynamic therapy - Authors' reply.
Topics: Aminolevulinic Acid; Aminoquinolines; Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Male; Pho | 2013 |
Efficacy of photodynamic therapy for treatment of basal cell carcinoma in organ transplant recipients.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Drug Screening Assays, Antitumor; Female; Humans; | 2015 |
Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Combined Chemot | 2014 |
5-Aminolevulinic acid based photodynamic therapy for basal cell carcinoma: a 10-years follow-up study.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Photochemotherapy; Photosensitizin | 2013 |
Daylight photodynamic therapy with methyl aminolaevulinate in patients with actinic keratoses: a preliminary experience in Southern Italy.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Italy; Keratosi | 2016 |
A prospective study of pain control by a 2-step irradiance schedule during topical photodynamic therapy of nonmelanoma skin cancer.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Middle Aged; Pain Man | 2014 |
Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal.
Topics: Aminolevulinic Acid; Aminoquinolines; Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Male; Pho | 2015 |
Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal'.
Topics: Aminolevulinic Acid; Aminoquinolines; Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Male; Pho | 2015 |
Commentary on 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial'.
Topics: Aminolevulinic Acid; Aminoquinolines; Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Male; Pho | 2015 |
Treatment of choice in superficial basal cell carcinoma.
Topics: Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Female; Humans; | 2015 |
Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Carcino | 2015 |
The choice and measurement of fluence in photodynamic therapy for superficial basal cell carcinoma.
Topics: Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Female; Humans; | 2015 |
The choice and measurement of fluence in photodynamic therapy for superficial basal cell carcinoma: reply from the authors.
Topics: Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Female; Humans; | 2015 |
A photodynamic therapy combined with topical 5-aminolevulinic acid and systemic hematoporphyrin derivative is more efficient but less phototoxic for cancer.
Topics: Adult; Aged; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous | 2016 |
Proposal of thermal imaging application in photodynamic therapy-Preliminary report.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Male; Photochemotherapy; Skin Neoplasms; Skin Te | 2016 |
Two-fold illumination in topical 5-aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) for superficial basal cell carcinoma (sBCC): A retrospective case series and cohort study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Cohort Studies; Confiden | 2016 |
Can basal cell carcinoma lateral border be determined by fluorescence diagnosis?: Verification by Mohs micrographic surgery.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Diagnostic Techniques, Surgical; Female; Fl | 2016 |
Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studie | 2016 |
Treatment failure in superficial basal cell carcinoma following treatment with photodynamic therapy: is this a result of underdiagnosis?
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Retrospective Studies; Skin N | 2017 |
Ingenol Mebutate vs. Daylight Photodynamic Therapy in a Kidney Transplant Recipient.
Topics: Aged; Aminolevulinic Acid; Antineoplastic Agents; Carcinogenesis; Carcinoma, Basal Cell; Carcinoma, | 2016 |
Long-term follow-up of patients with basal cell carcinoma after successful treatment with intralesional photodynamic therapy.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Disease-Free Survival; Follow-Up Studies; Humans; Inject | 2016 |
Topical photodynamic therapy for primary Bowen disease and basal cell carcinoma: optimizing patient selection.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Car | 2017 |
Update on new drugs in dermatology.
Topics: Aminolevulinic Acid; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agent | 2016 |
Optical coherence tomography imaging of basal cell carcinoma undergoing photodynamic therapy: A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Mi | 2017 |
Factors predicting pain and effect of oral analgesia in topical photodynamic therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Analgesics; Bowen's Disea | 2017 |
Letter: photodynamic therapy with methyl aminolevulinate induces phototoxic reactions on areas of the nose adjacent to basal cell carcinomas and actinic keratoses.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Dermatitis, Phototoxic; Humans; | 2008 |
Sequential treatment of giant basal cell carcinomas.
Topics: Administration, Topical; Aged; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Carcinom | 2009 |
Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Huma | 2008 |
Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream.
Topics: Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cel | 2008 |
Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Biological Availability; Carcinoma, Basal Cell; Chroma | 2008 |
Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Dimethyl Sulfoxide; Fema | 2009 |
Comparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Dose-Response Relationship, Dru | 2008 |
Preoperative assessment of basal cell carcinoma using conventional fluorescence diagnosis.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Diagnostic Imaging; Female; Flu | 2009 |
Microscopic distribution of protoporphyrin (PpIX) fluorescence in superficial basal cell carcinoma during light-fractionated aminolaevulinic acid photodynamic therapy.
Topics: Aminolevulinic Acid; Biopsy; Carcinoma, Basal Cell; Humans; Immunohistochemistry; Ki-67 Antigen; Mic | 2008 |
Photodynamic therapy for the treatment of a giant superficial basal cell carcinoma.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Male; Photochemotherapy | 2009 |
Sequential effects of photodynamic treatment of basal cell carcinoma.
Topics: Aminolevulinic Acid; Apoptosis; Carcinoma, Basal Cell; Cytokines; Humans; Immunohistochemistry; In S | 2009 |
An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cel | 2009 |
Treatment of skin cancer and pre-cancer using topical ALA-PDT--a single hospital experience.
Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamou | 2008 |
Methyl aminolaevulinate-photodynamic therapy for actinic keratoses, squamous cell carcinoma in situ and superficial basal cell carcinoma employing a square wave intense pulsed light device for photoactivation.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Photochemot | 2009 |
Calcitriol treatment improves methyl aminolaevulinate-based photodynamic therapy in human squamous cell carcinoma A431 cells.
Topics: Aminolevulinic Acid; Calcitriol; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2009 |
Photodynamic therapy of eyelid basal cell carcinoma.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Eyelid | 2009 |
Methyl-aminolevulinate photodynamic therapy for the treatment of actinic keratoses and non-melanoma skin cancers: a retrospective analysis of response in 462 patients.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squ | 2009 |
Topical photodynamic therapy with porphyrin precursors--assessment of treatment-associated pain in a retrospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Ke | 2009 |
Photodynamic therapy for tumors on the eyelid margins.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Eyelid Neoplasms; Humans; Middl | 2009 |
Simulations of measured photobleaching kinetics in human basal cell carcinomas suggest blood flow reductions during ALA-PDT.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Models, Cardiovascular; Photobleaching; Photoche | 2009 |
Fractionated 5-aminolevulinic acid photodynamic therapy in the treatment of a giant recurrent superficial basal cell carcinoma.
Topics: Adult; Aminolevulinic Acid; Carcinoma, Basal Cell; Dose Fractionation, Radiation; Humans; Male; Phot | 2009 |
[Fluorescence diagnostics of skin tumors using 5-aminolevulinic acid and its methyl ester].
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell | 2009 |
A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.
Topics: Aminolevulinic Acid; Aminoquinolines; Bowen's Disease; Carcinoma, Basal Cell; Cost-Benefit Analysis; | 2010 |
A comparison in real clinical practice of methyl aminolevulinate photodynamic therapy and surgery for small superficial basal cell carcinoma: 3-year recurrence rates and cosmetic outcomes.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Cohort Studies; Combined Modality Therapy; Humans; Photo | 2011 |
Rapid progression of a basal cell carcinoma after photodynamic therapy.
Topics: Aminolevulinic Acid; Biopsy; Carcinoma, Basal Cell; Disease Progression; Humans; Keratosis, Actinic; | 2010 |
Novel patch-based systems for the localised delivery of ALA-esters.
Topics: Administration, Topical; Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Disease Models, Animal | 2010 |
The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Female; Humans | 2010 |
The efficacy of photodynamic diagnosis in defining the lateral border between a tumor and a tumor-free area during Mohs micrographic surgery.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carci | 2010 |
Pre-surgical mapping of cutaneous non-melanoma carcinoma using topical methyl aminolevulinic acid.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Squamou | 2011 |
Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response.
Topics: Age Factors; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Extremities; Femal | 2011 |
[Periocular basal cell carcinoma treatment tendencies].
Topics: Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Conjunctival Neo | 2010 |
Tumor thickness predicts long-term complete response of facial basal cell carcinomas in Asian skin types iv/v treated with methyl aminolaevulinate photodynamic therapy.
Topics: Aminolevulinic Acid; Biopsy; Carcinoma, Basal Cell; Chi-Square Distribution; China; Facial Neoplasms | 2011 |
Photodynamic diagnosis of tumor margins using methyl aminolevulinate before Mohs micrographic surgery.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Femal | 2011 |
Monte Carlo modeling of in vivo protoporphyrin IX fluorescence and singlet oxygen production during photodynamic therapy for patients presenting with superficial basal cell carcinomas.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Models, Biological; Monte Carlo Method; Phantoms | 2011 |
Fluorescence diagnostics of basal cell carcinomas comparing methyl-aminolaevulinate and aminolaevulinic acid and correlation with visual clinical tumour size.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Aminolevulinic Acid; Automation, Laboratory; Carcinoma, | 2011 |
Photodynamic therapy as adjunctive therapy for morpheaform basal cell carcinoma.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Chemotherapy, Adjuvant; Chromosomes, Artificial, Bacteri | 2011 |
Evaluation of recurrence after photodynamic therapy with topical methylaminolaevulinate for 157 basal cell carcinomas in 90 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Hum | 2012 |
Photodynamic therapy of non-melanoma skin cancer with methyl aminolaevulinate is associated with less pain than with aminolaevulinic acid.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Analysis of Variance; Bowen's Disease; Carcinom | 2012 |
High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cel | 2012 |
Ultrasound guided ablative-laser assisted photodynamic therapy of basal cell carcinoma (US-aL-PDT).
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy, Needle; Carcinoma, Basal Cell; Cohort S | 2012 |
Photodynamic therapy for basal cell carcinomas in organ-transplant recipients.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studies; Humans; Immunoco | 2012 |
Facial extensive recurrent basal cell carcinoma: successful treatment with photodynamic therapy and imiquimod 5% cream.
Topics: Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cel | 2012 |
Intraoperative photodynamic therapy: a description of a new adjuvant technique for patients with nonmelanoma skin cancer.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Color; Combined Modality Thera | 2012 |
Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female | 2013 |
Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid?
Topics: Administration, Topical; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Male; | 2012 |
Reflectance confocal microscopy allows in vivo real-time noninvasive assessment of the outcome of methyl aminolaevulinate photodynamic therapy of basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Dermoscopy; Female; Foll | 2013 |
Urticaria after methyl aminolevulinate photodynamic therapy in a patient with nevoid basal cell carcinoma syndrome.
Topics: Aminolevulinic Acid; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Female; Humans; Middle Aged; | 2012 |
Noninvasive assessment for noninvasive treatments in dermato-oncology.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Microscopy, Confocal; Photochemoth | 2013 |
Daylight-mediated photodynamic therapy of basal cell carcinomas - an explorative study.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Back; Carcinoma, Basal Cell; Facial Neoplasms; | 2014 |
A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal C | 2013 |
Evaluation of photodynamic therapy of skin cancers with partial differential alpha-aminolevulinic acid.
Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Follow-Up | 2002 |
[An unsurpassed duo in control of skin cancer. Metvix and Aktilite].
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Cell Survival; Hematoporphyrin | 2003 |
Kinetics of the superficial perfusion and temperature in connection with photodynamic therapy of basal cell carcinomas using esterified and non-esterified 5-aminolaevulinic acid.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Laser-Doppler Fl | 2003 |
Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; England | 2003 |
[In actinic keratosis and basal cell carcinoma. The power of light heals without scars].
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratosis; Middle Aged; Ointments; Photoch | 2003 |
Evaluation of the penetration of 5-aminolevulinic acid through basal cell carcinoma: a pilot study.
Topics: Aged; Aminolevulinic Acid; Biopsy; Carcinoma, Basal Cell; Chromatography, High Pressure Liquid; Cryo | 2004 |
[Eliminating light-induced skin cancer without operation].
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Hematoporphyrin Photoradiation; | 2004 |
Recurrence rate of basal cell carcinoma after topical aminolevulinic acid-based photodynamic therapy.
Topics: Administration, Topical; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Neo | 2004 |
Discrete choice experiment to derive willingness to pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell carcinoma.
Topics: Adult; Aged; Aminolevulinic Acid; Attitude; Carcinoma, Basal Cell; Costs and Cost Analysis; Female; | 2004 |
Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; | 2005 |
Photodynamic diagnosis of non-melanoma skin cancer.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photofluorography; Skin | 2005 |
Treatment of basal cell carcinoma with topical methylaminolaevulinate photodynamic therapy in an organ-transplant recipient.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Liver Transplan | 2006 |
[Reader's letter concerning K. Kreutzer, B.Bonnekoh, I. Franke, H. Gollnick. Photodynamic therapy with methylaminooxopentanoate (Metvix) and a broad band light source (Photdyn 501): practical experiences in problem patients with actinic keratoses and basa
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratosis; Photochemotherapy; Photosensitivity D | 2005 |
Bispectral fluorescence imaging of aggressive basal cell carcinoma combined with histopathological mapping: a preliminary study indicating a possible adjunct to Mohs micrographic surgery.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Facial Neoplasms; Female | 2006 |
Broad area photodynamic therapy for treatment of multiple basal cell carcinomas in a patient with nevoid basal cell carcinoma syndrome.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Male; Photochemotherapy; Photosensitizing | 2006 |
The use of photodynamic therapy in dermatology: results of a consensus conference.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Clinical Trials as Topic; Humans; Keratosis; Photochemot | 2006 |
In vitro percutaneous absorption and in vivo protoporphyrin IX accumulation in skin and tumors after topical 5-aminolevulinic acid application with enhancement using an erbium:YAG laser.
Topics: Administration, Cutaneous; Aluminum; Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Cell Line, | 2006 |
Multiple large surface photodynamic therapy sessions with topical methylaminolaevulinate in PTCH heterozygous mice.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Female; Genetic Predisposition to Disease; Hete | 2006 |
Unilateral Basal cell carcinomas: an unusual entity treated with photodynamic therapy.
Topics: Aminolevulinic Acid; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Diagnosis, Differential; Foll | 2005 |
Late erythema after photodynamic therapy to the face.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Carcinoma, Basal Cell; Cheek; Erythema; Humans; | 2006 |
Clinical and research applications of photodynamic therapy in dermatology: experience of the Scottish PDT Centre.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis; Neoplasm Recurrence, | 2006 |
Epidermoid cysts mimicking recurrence of superficial basal cell carcinoma following photodynamic therapy.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Diagnosis, Differential; Epidermal Cyst; Female; Humans; | 2007 |
Photodetection of basal cell carcinoma using methyl 5-aminolaevulinate-induced protoporphyrin IX based on fluorescence image analysis.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Facial Neoplasms; Female; Humans; Male; Middle Age | 2007 |
Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Female; | 2008 |
Nodular basal cell carcinoma: when in doubt, cut it out.
Topics: Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Humans; Imiquimo | 2007 |
Pathologic changes after photodynamic therapy for Basal cell carcinoma and Bowen disease: a histologic and immunohistochemical investigation.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Apoptosis; Biopsy; Bowen's Disease; Carcinoma, Basal C | 2008 |
A pilot study of fluorescence diagnosis of basal cell carcinoma using a digital flash light-based imaging system.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Diagnostic Imaging; Female; Flu | 2008 |
Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Deferoxamine; Female; Humans; Keratosis | 1995 |
Unilateral localized basaliomatosis: treatment with topical photodynamic therapy after application of 5-aminolevulinic acid.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Basal Cell Nevus Syndrome; Carcinoma, Basal Ce | 1995 |
[Topical photodynamic therapy in treatment of superficial skin tumors].
Topics: Aged; Aminolevulinic Acid; Biopsy; Bowen's Disease; Carcinoma, Basal Cell; Female; Humans; Male; Mid | 1995 |
Temperature monitoring during photodynamic therapy of skin tumors with topical 5-aminolevulinic acid application.
Topics: Aminolevulinic Acid; Body Temperature; Carcinoma, Basal Cell; Facial Dermatoses; Facial Neoplasms; H | 1995 |
[Photodynamic diagnosis and therapy of neoplasms of the facial skin after topical administration of 5-aminolevulinic acid].
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Facial | 1995 |
Photodynamic therapy of nonmelanoma skin cancer with topical aminolevulinic acid: a clinical and histologic study.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Basal Cell; Carc | 1995 |
[Photodynamic therapy of eyelid basalioma after topical administration of delta-aminolevulinic acid].
Topics: Administration, Topical; Aged; Aminolevulinic Acid; Biopsy; Carcinoma, Basal Cell; Eyelid Neoplasms; | 1994 |
Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Arm; Bowen's Disease; | 1994 |
Penetration potency of topical applied delta-aminolevulinic acid for photodynamic therapy of basal cell carcinoma.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Microscopy, Fluorescenc | 1994 |
Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas?
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cel | 1993 |
Problems associated with the use of broad-band illumination sources for photodynamic therapy.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Infrared Rays; Light; Photochemotherapy; Photose | 1995 |
Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Dimethyl Sulfoxide; Huma | 1995 |
[Photodynamic therapy and breast-plasty of a extensive superficial trunk skin basalioma of the breast. An effective combination therapy with photodynamic diagnosis].
Topics: Administration, Topical; Aminolevulinic Acid; Breast Neoplasms; Carcinoma, Basal Cell; Combined Moda | 1996 |
Influence of topical photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism.
Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratosis; Photochemoth | 1996 |
Photodynamic treatment of skin malignancies with aminolevulinic acid. Emphasis on anatomical observations and in vivo erythema visual assessment.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Basal Cell; Erythema; Female; Follow-Up Studi | 1996 |
Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues.
Topics: Adenocarcinoma; Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Drug Interactions; Humans; Live | 1997 |
Ex vivo application of delta-aminolevulinic acid induces high and specific porphyrin levels in human skin tumors: possible basis for selective photodynamic therapy.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratoacanthoma; Kinetics; Organ Culture Techniq | 1997 |
The kinetics of protoporphyrin fluorescence during ALA-PDT in human malignant skin tumors.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorescence; Humans; Photoche | 1997 |
Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cel | 1998 |
Modified topical photodynamic therapy of superficial skin tumors, utilizing aminolevulinic acid, penetration enhancers, red light, and hyperthermia.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcin | 1998 |
Photodynamic therapy utilising topical delta-aminolevulinic acid in non-melanoma skin malignancies of the eyelid and the periocular skin.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; | 1999 |
Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study.
Topics: Administration, Topical; Aminolevulinic Acid; Anti-Inflammatory Agents; Biopsy; Carcinoma, Basal Cel | 1999 |
Photodynamic diagnosis of basal cell carcinoma on the lower eyelid using topical 5-aminolaevulinic acid and desferrioxamine.
Topics: Adult; Aminolevulinic Acid; Carcinoma, Basal Cell; Deferoxamine; Eyelid Neoplasms; Humans; Male; Pho | 1999 |
Repeated 5-aminolevulinic acid-based photodynamic therapy following electro-curettage for pigmented basal cell carcinoma.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Curettage; Female; Humans; Ligh | 2000 |
Delta-aminolevulinic acid in superficial basal cell carcinomas and normal skin-a microdialysis and perfusion study.
Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Chromatography, Ion Exchange; Female; Humans; Male | 2000 |
[Fluorescence-assisted biopsy of basal cell carcinomas].
Topics: Administration, Topical; Aminolevulinic Acid; Biopsy; Carcinoma, Basal Cell; Fluorescence; Humans; I | 2000 |
The application of a compact multispectral imaging system with integrated excitation source to in vivo monitoring of fluorescence during topical photodynamic therapy of superficial skin cancers.
Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Fluorescence; Humans; Photochemotherapy | 2001 |
Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Carcinogenicity Tests; Carcinoma, Basal Cell; Cyclooxygenas | 2001 |
Topical photodynamic therapy at low fluence rates--theory and practice.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; | 2001 |
An affordable, portable fluorescence imaging device for skin lesion detection using a dual wavelength approach for image contrast enhancement and aminolaevulinic acid-induced protoporphyrin IX. Part II. In vivo testing.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Female; Humans; Mice; Mice, Inbred BALB C; Phot | 2001 |
A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Esth | 2001 |
Porphyrins and nucleic acid in some photosensitive skin diseases.
Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; DNA; Hemoglobins; Humans; Porphyrins; Protoporphyrins; R | 1990 |
Pemphigus vulgaris induced by 5-aminolaevulinic acid-based photodynamic therapy.
Topics: Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Levulinic Acids; Pemp | 2017 |
Nanostructured lipid carrier in photodynamic therapy for the treatment of basal-cell carcinoma.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Carcinoma, Basal Cell; Cell Line, Tumor; Delayed-Act | 2016 |